0001812727 true Q1 2022 --12-31 0001812727 2022-01-01 2022-03-31 0001812727 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001812727 RELI:SeriesAWarrantsMember 2022-01-01 2022-03-31 0001812727 2022-05-16 0001812727 2022-03-31 0001812727 2021-12-31 0001812727 2021-01-01 2021-03-31 0001812727 us-gaap:PreferredStockMember 2021-12-31 0001812727 us-gaap:CommonStockMember 2021-12-31 0001812727 RELI:CommonStockIssuableMember 2021-12-31 0001812727 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001812727 RELI:SubscriptionReceivableMember 2021-12-31 0001812727 us-gaap:RetainedEarningsMember 2021-12-31 0001812727 us-gaap:PreferredStockMember 2020-12-31 0001812727 us-gaap:CommonStockMember 2020-12-31 0001812727 RELI:CommonStockIssuableMember 2020-12-31 0001812727 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001812727 us-gaap:RetainedEarningsMember 2020-12-31 0001812727 2020-12-31 0001812727 us-gaap:PreferredStockMember 2022-01-01 2022-03-31 0001812727 RELI:CommonStockIssuableMember 2022-01-01 2022-03-31 0001812727 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001812727 RELI:SubscriptionReceivableMember 2022-01-01 2022-03-31 0001812727 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001812727 us-gaap:PreferredStockMember 2021-01-01 2021-03-31 0001812727 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001812727 RELI:CommonStockIssuableMember 2021-01-01 2021-03-31 0001812727 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001812727 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001812727 us-gaap:PreferredStockMember 2022-03-31 0001812727 us-gaap:CommonStockMember 2022-03-31 0001812727 RELI:CommonStockIssuableMember 2022-03-31 0001812727 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001812727 RELI:SubscriptionReceivableMember 2022-03-31 0001812727 us-gaap:RetainedEarningsMember 2022-03-31 0001812727 us-gaap:PreferredStockMember 2021-03-31 0001812727 us-gaap:CommonStockMember 2021-03-31 0001812727 RELI:CommonStockIssuableMember 2021-03-31 0001812727 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001812727 us-gaap:RetainedEarningsMember 2021-03-31 0001812727 2021-03-31 0001812727 us-gaap:OverAllotmentOptionMember 2021-01-01 2021-03-31 0001812727 srt:RestatementAdjustmentMember 2022-01-01 2022-03-31 0001812727 RELI:PurchaseAgreementMember 2022-03-31 0001812727 us-gaap:FairValueInputsLevel3Member 2022-03-31 0001812727 us-gaap:FairValueInputsLevel3Member 2021-12-31 0001812727 srt:MinimumMember 2022-01-01 2022-03-31 0001812727 srt:MaximumMember 2022-01-01 2022-03-31 0001812727 srt:ScenarioPreviouslyReportedMember 2022-01-01 2022-03-31 0001812727 us-gaap:ComputerEquipmentMember 2022-01-01 2022-03-31 0001812727 RELI:OfficeEquipmentAndFurnitureMember 2022-01-01 2022-03-31 0001812727 us-gaap:LeaseholdImprovementsMember 2022-01-01 2022-03-31 0001812727 us-gaap:MeasurementInputSharePriceMember 2022-03-31 0001812727 us-gaap:MeasurementInputSharePriceMember 2021-12-31 0001812727 us-gaap:MeasurementInputPriceVolatilityMember 2022-03-31 0001812727 us-gaap:MeasurementInputPriceVolatilityMember 2021-12-31 0001812727 us-gaap:MeasurementInputExpectedTermMember 2022-03-31 0001812727 us-gaap:MeasurementInputExpectedTermMember 2021-12-31 0001812727 us-gaap:MeasurementInputExpectedDividendRateMember 2022-03-31 0001812727 us-gaap:MeasurementInputExpectedDividendRateMember 2021-12-31 0001812727 us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-03-31 0001812727 us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-12-31 0001812727 RELI:SeriesBWarrantCommitmentMember 2021-12-31 0001812727 RELI:SeriesBWarrantLiabilityMember 2021-12-31 0001812727 RELI:PlacementAgentWarrantsMember 2021-12-31 0001812727 RELI:SeriesBWarrantCommitmentMember 2022-01-01 2022-03-31 0001812727 RELI:SeriesBWarrantLiabilityMember 2022-01-01 2022-03-31 0001812727 RELI:PlacementAgentWarrantsMember 2022-01-01 2022-03-31 0001812727 RELI:SeriesBWarrantCommitmentMember 2022-03-31 0001812727 RELI:SeriesBWarrantLiabilityMember 2022-03-31 0001812727 RELI:PlacementAgentWarrantsMember 2022-03-31 0001812727 RELI:SeriesBWarrantCommitmentMember 2020-12-31 0001812727 RELI:SeriesBWarrantCommitmentMember 2021-01-01 2021-12-31 0001812727 2021-01-01 2021-12-31 0001812727 us-gaap:FairValueInputsLevel3Member 2020-12-31 0001812727 us-gaap:FairValueInputsLevel3Member 2022-01-01 2022-03-31 0001812727 us-gaap:FairValueInputsLevel3Member 2021-01-01 2021-03-31 0001812727 us-gaap:FairValueInputsLevel3Member RELI:JPKushAcquisitionMember 2022-01-01 2022-03-31 0001812727 us-gaap:FairValueInputsLevel3Member RELI:JPKushAcquisitionMember 2021-01-01 2021-03-31 0001812727 us-gaap:FairValueInputsLevel3Member RELI:CCSWriteoffMember 2022-01-01 2022-03-31 0001812727 us-gaap:FairValueInputsLevel3Member RELI:CCSWriteoffMember 2021-01-01 2021-03-31 0001812727 us-gaap:FairValueInputsLevel3Member RELI:AltruisPartialSettlementMember 2022-01-01 2022-03-31 0001812727 us-gaap:FairValueInputsLevel3Member RELI:AltruisPartialSettlementMember 2021-01-01 2021-03-31 0001812727 us-gaap:FairValueInputsLevel3Member 2021-03-31 0001812727 us-gaap:FairValueInputsLevel3Member 2021-01-01 2021-12-31 0001812727 RELI:MedicalLifeMember RELI:RegularMember RELI:EmployeeBenefitsSolutionsLLCMember 2022-01-01 2022-03-31 0001812727 RELI:PropertyAndCasualtyMember RELI:RegularMember RELI:EmployeeBenefitsSolutionsLLCMember 2022-01-01 2022-03-31 0001812727 RELI:EmployeeBenefitsSolutionsLLCMember 2022-01-01 2022-03-31 0001812727 RELI:MedicalLifeMember RELI:RegularMember RELI:USBenefitsAllianceLLCMember 2022-01-01 2022-03-31 0001812727 RELI:PropertyAndCasualtyMember RELI:RegularMember RELI:USBenefitsAllianceLLCMember 2022-01-01 2022-03-31 0001812727 RELI:USBenefitsAllianceLLCMember 2022-01-01 2022-03-31 0001812727 RELI:MedicalLifeMember RELI:RegularMember RELI:CommercialCoverageSolutionsLLCMember 2022-01-01 2022-03-31 0001812727 RELI:PropertyAndCasualtyMember RELI:RegularMember RELI:CommercialCoverageSolutionsLLCMember 2022-01-01 2022-03-31 0001812727 RELI:CommercialCoverageSolutionsLLCMember 2022-01-01 2022-03-31 0001812727 RELI:MedicalLifeMember RELI:RegularMember RELI:SouthwesternMontanaFinancialCenterIncMember 2022-01-01 2022-03-31 0001812727 RELI:PropertyAndCasualtyMember RELI:RegularMember RELI:SouthwesternMontanaFinancialCenterIncMember 2022-01-01 2022-03-31 0001812727 RELI:SouthwesternMontanaFinancialCenterIncMember 2022-01-01 2022-03-31 0001812727 RELI:MedicalLifeMember RELI:RegularMember RELI:FortmanInsuranceServicesLLCMember 2022-01-01 2022-03-31 0001812727 RELI:PropertyAndCasualtyMember RELI:RegularMember RELI:FortmanInsuranceServicesLLCMember 2022-01-01 2022-03-31 0001812727 RELI:FortmanInsuranceServicesLLCMember 2022-01-01 2022-03-31 0001812727 RELI:MedicalLifeMember RELI:RegularMember RELI:AltruisBenefitsConsultingIncMember 2022-01-01 2022-03-31 0001812727 RELI:PropertyAndCasualtyMember RELI:RegularMember RELI:AltruisBenefitsConsultingIncMember 2022-01-01 2022-03-31 0001812727 RELI:AltruisBenefitsConsultingIncMember 2022-01-01 2022-03-31 0001812727 RELI:MedicalLifeMember RELI:RegularMember RELI:KushMember 2022-01-01 2022-03-31 0001812727 RELI:PropertyAndCasualtyMember RELI:RegularMember RELI:KushMember 2022-01-01 2022-03-31 0001812727 RELI:KushMember 2022-01-01 2022-03-31 0001812727 RELI:MedicalLifeMember RELI:RegularMember RELI:MedigapMember 2022-01-01 2022-03-31 0001812727 RELI:PropertyAndCasualtyMember RELI:RegularMember RELI:MedigapMember 2022-01-01 2022-03-31 0001812727 RELI:MedigapMember 2022-01-01 2022-03-31 0001812727 RELI:MedicalLifeMember RELI:RegularMember 2022-01-01 2022-03-31 0001812727 RELI:PropertyAndCasualtyMember RELI:RegularMember 2022-01-01 2022-03-31 0001812727 RELI:MedicalLifeMember RELI:RegularMember RELI:EmployeeBenefitsSolutionsLLCMember 2021-01-01 2021-03-31 0001812727 RELI:PropertyAndCasualtyMember RELI:RegularMember RELI:EmployeeBenefitsSolutionsLLCMember 2021-01-01 2021-03-31 0001812727 RELI:ContingentCommissionMember RELI:RegularMember RELI:EmployeeBenefitsSolutionsLLCMember 2021-01-01 2021-03-31 0001812727 RELI:EmployeeBenefitsSolutionsLLCMember 2021-01-01 2021-03-31 0001812727 RELI:MedicalLifeMember RELI:RegularMember RELI:USBenefitsAllianceLLCMember 2021-01-01 2021-03-31 0001812727 RELI:PropertyAndCasualtyMember RELI:RegularMember RELI:USBenefitsAllianceLLCMember 2021-01-01 2021-03-31 0001812727 RELI:ContingentCommissionMember RELI:RegularMember RELI:USBenefitsAllianceLLCMember 2021-01-01 2021-03-31 0001812727 RELI:USBenefitsAllianceLLCMember 2021-01-01 2021-03-31 0001812727 RELI:MedicalLifeMember RELI:RegularMember RELI:CommercialCoverageSolutionsLLCMember 2021-01-01 2021-03-31 0001812727 RELI:PropertyAndCasualtyMember RELI:RegularMember RELI:CommercialCoverageSolutionsLLCMember 2021-01-01 2021-03-31 0001812727 RELI:ContingentCommissionMember RELI:RegularMember RELI:CommercialCoverageSolutionsLLCMember 2021-01-01 2021-03-31 0001812727 RELI:CommercialCoverageSolutionsLLCMember 2021-01-01 2021-03-31 0001812727 RELI:MedicalLifeMember RELI:RegularMember RELI:SouthwesternMontanaFinancialCenterIncMember 2021-01-01 2021-03-31 0001812727 RELI:PropertyAndCasualtyMember RELI:RegularMember RELI:SouthwesternMontanaFinancialCenterIncMember 2021-01-01 2021-03-31 0001812727 RELI:ContingentCommissionMember RELI:RegularMember RELI:SouthwesternMontanaFinancialCenterIncMember 2021-01-01 2021-03-31 0001812727 RELI:SouthwesternMontanaFinancialCenterIncMember 2021-01-01 2021-03-31 0001812727 RELI:MedicalLifeMember RELI:RegularMember RELI:FortmanInsuranceServicesLLCMember 2021-01-01 2021-03-31 0001812727 RELI:PropertyAndCasualtyMember RELI:RegularMember RELI:FortmanInsuranceServicesLLCMember 2021-01-01 2021-03-31 0001812727 RELI:ContingentCommissionMember RELI:RegularMember RELI:FortmanInsuranceServicesLLCMember 2021-01-01 2021-03-31 0001812727 RELI:FortmanInsuranceServicesLLCMember 2021-01-01 2021-03-31 0001812727 RELI:MedicalLifeMember RELI:RegularMember RELI:AltruisBenefitsConsultingIncMember 2021-01-01 2021-03-31 0001812727 RELI:PropertyAndCasualtyMember RELI:RegularMember RELI:AltruisBenefitsConsultingIncMember 2021-01-01 2021-03-31 0001812727 RELI:ContingentCommissionMember RELI:RegularMember RELI:AltruisBenefitsConsultingIncMember 2021-01-01 2021-03-31 0001812727 RELI:AltruisBenefitsConsultingIncMember 2021-01-01 2021-03-31 0001812727 RELI:MedicalLifeMember RELI:RegularMember 2021-01-01 2021-03-31 0001812727 RELI:PropertyAndCasualtyMember RELI:RegularMember 2021-01-01 2021-03-31 0001812727 RELI:ContingentCommissionMember RELI:RegularMember 2021-01-01 2021-03-31 0001812727 srt:ScenarioPreviouslyReportedMember 2020-12-31 0001812727 srt:RestatementAdjustmentMember 2020-12-31 0001812727 srt:ScenarioPreviouslyReportedMember 2021-03-31 0001812727 srt:RestatementAdjustmentMember 2021-03-31 0001812727 srt:ScenarioPreviouslyReportedMember 2021-01-01 2021-03-31 0001812727 srt:RestatementAdjustmentMember 2021-01-01 2021-03-31 0001812727 RELI:JPKushAndAssociatesIncMember 2021-04-25 2021-05-01 0001812727 RELI:JPKushAndAssociatesIncMember 2021-05-01 0001812727 RELI:JPKushAndAssociatesIncMember 2021-01-01 2021-04-30 0001812727 RELI:MedigapHealthcareInsuranceCompanyMember 2022-01-08 2022-01-10 0001812727 RELI:MeasurementInputRoyaltyRateMember us-gaap:TradeNamesMember 2022-03-31 0001812727 us-gaap:MeasurementInputDiscountRateMember us-gaap:TradeNamesMember 2022-03-31 0001812727 us-gaap:MeasurementInputDiscountRateMember us-gaap:CustomerRelationshipsMember 2022-03-31 0001812727 RELI:MeasurementInputObsolescenceRateMember us-gaap:TechnologyBasedIntangibleAssetsMember 2022-03-31 0001812727 us-gaap:MeasurementInputDiscountRateMember RELI:BackLogMember 2022-03-31 0001812727 RELI:MedigapHealthcareInsuranceCompanyMember 2022-03-31 0001812727 RELI:MedigapHealthcareInsuranceCompanyMember 2022-01-01 2022-03-31 0001812727 RELI:MedigapHealthcareInsuranceCompanyMember 2021-01-01 2021-12-31 0001812727 RELI:JPKushAndAssociatesIncMember 2022-01-01 2022-03-31 0001812727 RELI:JPKushAndAssociatesIncMember RELI:TradeNameAndTrademarksMember 2021-04-28 2021-05-01 0001812727 RELI:JPKushAndAssociatesIncMember us-gaap:CustomerRelationshipsMember 2021-04-28 2021-05-01 0001812727 RELI:JPKushAndAssociatesIncMember RELI:NoncompetitionAgreementsMember 2021-04-28 2021-05-01 0001812727 RELI:JPKushAndAssociatesIncMember us-gaap:GoodwillMember 2021-04-28 2021-05-01 0001812727 RELI:JPKushAndAssociatesIncMember 2022-03-31 0001812727 RELI:MedigapHealthcareInsuranceCompanyMember us-gaap:PropertyPlantAndEquipmentMember 2022-03-31 0001812727 RELI:MedigapHealthcareInsuranceCompanyMember us-gaap:PropertyPlantAndEquipmentMember 2022-01-01 2022-03-31 0001812727 RELI:MedigapHealthcareInsuranceCompanyMember RELI:RightOfUseAssetMember 2022-03-31 0001812727 RELI:MedigapHealthcareInsuranceCompanyMember us-gaap:TradeNamesMember 2022-03-31 0001812727 RELI:MedigapHealthcareInsuranceCompanyMember us-gaap:TradeNamesMember 2022-01-01 2022-03-31 0001812727 RELI:MedigapHealthcareInsuranceCompanyMember us-gaap:CustomerRelationshipsMember 2022-03-31 0001812727 RELI:MedigapHealthcareInsuranceCompanyMember us-gaap:CustomerRelationshipsMember 2022-01-01 2022-03-31 0001812727 RELI:MedigapHealthcareInsuranceCompanyMember us-gaap:TechnologyBasedIntangibleAssetsMember 2022-03-31 0001812727 RELI:MedigapHealthcareInsuranceCompanyMember us-gaap:TechnologyBasedIntangibleAssetsMember 2022-01-01 2022-03-31 0001812727 RELI:MedigapHealthcareInsuranceCompanyMember RELI:BackLogMember 2022-03-31 0001812727 RELI:MedigapHealthcareInsuranceCompanyMember RELI:BackLogMember 2022-01-01 2022-03-31 0001812727 RELI:MedigapHealthcareInsuranceCompanyMember RELI:ChargebackReserveMember 2022-03-31 0001812727 RELI:MedigapHealthcareInsuranceCompanyMember RELI:LeaseLiabilityMember 2022-03-31 0001812727 RELI:MedigapHealthcareInsuranceCompanyMember us-gaap:GoodwillMember 2022-03-31 0001812727 RELI:MedigapHealthcareInsuranceCompanyMember us-gaap:GoodwillMember 2022-01-01 2022-03-31 0001812727 RELI:MedigapHealthcareInsuranceCompanyMember 2021-01-01 2021-03-31 0001812727 RELI:SecuritiesPurchaseAgreementMember RELI:NSUREIncMember srt:MaximumMember 2020-02-19 0001812727 RELI:SecuritiesPurchaseAgreementMember RELI:NSUREIncMember us-gaap:CommonClassAMember 2020-02-18 2020-02-19 0001812727 RELI:SecuritiesPurchaseAgreementMember RELI:NSUREIncMember us-gaap:CommonClassAMember 2020-02-19 0001812727 RELI:SecuritiesPurchaseAgreementMember RELI:NSUREIncMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2020-02-19 0001812727 RELI:SecuritiesPurchaseAgreementMember RELI:NSUREIncMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2020-02-18 2020-02-19 0001812727 RELI:SecuritiesPurchaseAgreementMember RELI:NSUREIncMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2020-02-19 0001812727 RELI:SecuritiesPurchaseAgreementMember RELI:NSUREIncMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2022-03-31 0001812727 RELI:SecuritiesPurchaseAgreementMember RELI:NSUREIncMember us-gaap:CommonClassAMember 2020-06-01 0001812727 RELI:SecuritiesPurchaseAgreementMember RELI:NSUREIncMember us-gaap:CommonClassAMember 2020-05-29 2020-06-01 0001812727 RELI:SecuritiesPurchaseAgreementMember RELI:NSUREIncMember us-gaap:CommonClassAMember 2020-08-05 0001812727 RELI:SecuritiesPurchaseAgreementMember RELI:NSUREIncMember us-gaap:CommonClassAMember 2020-08-20 0001812727 RELI:SecuritiesPurchaseAgreementMember RELI:NSUREIncMember us-gaap:CommonClassAMember 2020-08-04 2020-08-05 0001812727 RELI:SecuritiesPurchaseAgreementMember RELI:NSUREIncMember us-gaap:CommonClassAMember 2020-08-19 2020-08-20 0001812727 RELI:SecuritiesPurchaseAgreementMember RELI:NSUREIncMember us-gaap:CommonClassAMember 2022-03-31 0001812727 RELI:ThirdPartyIndividualMember RELI:NSUREIncMember 2020-02-09 2020-02-10 0001812727 us-gaap:ComputerEquipmentMember 2022-03-31 0001812727 us-gaap:ComputerEquipmentMember 2021-12-31 0001812727 RELI:OfficeEquipmentAndFurnitureMember 2022-03-31 0001812727 RELI:OfficeEquipmentAndFurnitureMember 2021-12-31 0001812727 us-gaap:LeaseholdImprovementsMember 2022-03-31 0001812727 us-gaap:LeaseholdImprovementsMember 2021-12-31 0001812727 us-gaap:TrademarksAndTradeNamesMember 2022-01-01 2022-03-31 0001812727 us-gaap:TrademarksAndTradeNamesMember 2022-03-31 0001812727 RELI:InternallyDevelopedSoftwareMember 2022-01-01 2022-03-31 0001812727 RELI:InternallyDevelopedSoftwareMember 2022-03-31 0001812727 us-gaap:CustomerRelationshipsMember 2022-01-01 2022-03-31 0001812727 us-gaap:CustomerRelationshipsMember 2022-03-31 0001812727 RELI:PurchasedSoftwareMember 2022-01-01 2022-03-31 0001812727 RELI:PurchasedSoftwareMember 2022-03-31 0001812727 RELI:VideoProductionAssetsMember 2022-01-01 2022-03-31 0001812727 RELI:VideoProductionAssetsMember 2022-03-31 0001812727 RELI:NoncompetitionAgreementsMember 2022-01-01 2022-03-31 0001812727 RELI:NoncompetitionAgreementsMember 2022-03-31 0001812727 RELI:ContractsBacklogMember 2022-01-01 2022-03-31 0001812727 RELI:ContractsBacklogMember 2022-03-31 0001812727 us-gaap:TrademarksAndTradeNamesMember 2021-01-01 2021-12-31 0001812727 us-gaap:TrademarksAndTradeNamesMember 2021-12-31 0001812727 RELI:InternallyDevelopedSoftwareMember 2021-01-01 2021-12-31 0001812727 RELI:InternallyDevelopedSoftwareMember 2021-12-31 0001812727 us-gaap:CustomerRelationshipsMember 2021-01-01 2021-12-31 0001812727 us-gaap:CustomerRelationshipsMember 2021-12-31 0001812727 RELI:PurchasedSoftwareMember 2021-01-01 2021-12-31 0001812727 RELI:PurchasedSoftwareMember 2021-12-31 0001812727 RELI:VideoProductionAssetsMember 2021-01-01 2021-12-31 0001812727 RELI:VideoProductionAssetsMember 2021-12-31 0001812727 RELI:NoncompetitionAgreementsMember 2021-01-01 2021-12-31 0001812727 RELI:NoncompetitionAgreementsMember 2021-12-31 0001812727 RELI:EBSandUSBAMember 2022-03-31 0001812727 RELI:EBSandUSBAMember 2021-12-31 0001812727 RELI:CCSMember 2022-03-31 0001812727 RELI:CCSMember 2021-12-31 0001812727 RELI:SWMTMember 2022-03-31 0001812727 RELI:SWMTMember 2021-12-31 0001812727 RELI:FISMember 2022-03-31 0001812727 RELI:FISMember 2021-12-31 0001812727 RELI:ABCMember 2022-03-31 0001812727 RELI:ABCMember 2021-12-31 0001812727 RELI:EmployeeBenefitsSolutionsLLCAndUSBenefitsAllianceMember RELI:CreditAgreementMember RELI:OakStreetFundingLLCMember 2018-08-01 0001812727 RELI:EmployeeBenefitsSolutionsLLCAndUSBenefitsAllianceMember RELI:CreditAgreementMember RELI:OakStreetFundingLLCMember 2018-07-30 2018-08-01 0001812727 RELI:EmployeeBenefitsSolutionsLLCAndUSBenefitsAllianceMember RELI:CreditAgreementMember RELI:OakStreetFundingLLCMember 2018-12-31 0001812727 RELI:CommercialCoverageSolutionsLLCMember RELI:SeniorSecuredAmortizingCreditFacilityMember RELI:OakStreetFundingLLCMember 2018-12-07 0001812727 RELI:CommercialCoverageSolutionsLLCMember RELI:SeniorSecuredAmortizingCreditFacilityMember RELI:OakStreetFundingLLCMember 2018-12-06 2018-12-07 0001812727 RELI:CommercialCoverageSolutionsLLCMember RELI:SeniorSecuredAmortizingCreditFacilityMember RELI:OakStreetFundingLLCMember us-gaap:PrimeRateMember 2018-12-07 0001812727 RELI:CommercialCoverageSolutionsLLCMember RELI:SeniorSecuredAmortizingCreditFacilityMember RELI:OakStreetFundingLLCMember 2018-12-31 0001812727 RELI:CommercialCoverageSolutionsLLCMember RELI:TermLoanMember RELI:OakStreetFundingLLCMember 2019-12-31 0001812727 RELI:CommercialCoverageSolutionsLLCMember RELI:TermLoanMember RELI:OakStreetFundingLLCMember 2019-01-01 2019-12-31 0001812727 RELI:CommercialCoverageSolutionsLLCMember RELI:SeniorSecuredAmortizingCreditFacilityMember RELI:OakStreetFundingLLCMember us-gaap:PrimeRateMember 2019-12-31 0001812727 us-gaap:CommonStockMember RELI:SecuritiesPurchaseAgreementMember srt:MaximumMember 2021-12-22 0001812727 RELI:SecuritiesPurchaseAgreementMember 2021-12-22 0001812727 us-gaap:CommonStockMember RELI:SecuritiesPurchaseAgreementMember 2021-12-22 0001812727 us-gaap:CommonStockMember RELI:SecuritiesPurchaseAgreementMember 2021-12-22 2021-12-22 0001812727 RELI:SeriesBConvertiblePreferredStockMember RELI:SecuritiesPurchaseAgreementMember 2021-12-22 2021-12-22 0001812727 RELI:SeriesBConvertiblePreferredStockMember RELI:SecuritiesPurchaseAgreementMember 2021-12-22 0001812727 RELI:SecuritiesPurchaseAgreementMember 2021-01-01 2021-12-31 0001812727 RELI:SecuritiesPurchaseAgreementMember us-gaap:PrivatePlacementMember 2022-01-05 0001812727 RELI:SecuritiesPurchaseAgreementMember us-gaap:PrivatePlacementMember 2022-01-04 2022-01-05 0001812727 us-gaap:PrivatePlacementMember RELI:SecuritiesPurchaseAgreementMember 2022-01-01 2022-03-31 0001812727 us-gaap:PrivatePlacementMember RELI:SecuritiesPurchaseAgreementMember 2022-03-31 0001812727 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember RELI:CustomerMember 2021-01-01 2021-12-31 0001812727 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember RELI:BlueCrossBlueShieldMember 2022-01-01 2022-03-31 0001812727 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember RELI:BlueCrossBlueShieldMember 2021-01-01 2021-03-31 0001812727 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember RELI:PriorityHealthMember 2022-01-01 2022-03-31 0001812727 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember RELI:PriorityHealthMember 2021-01-01 2021-03-31 0001812727 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember RELI:LTCGlobalMember 2022-01-01 2022-03-31 0001812727 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember RELI:LTCGlobalMember 2021-01-01 2021-03-31 0001812727 us-gaap:SeriesAPreferredStockMember 2022-03-31 0001812727 RELI:SeriesBConvertiblePreferredStockMember 2022-03-31 0001812727 us-gaap:SeriesBPreferredStockMember 2022-03-31 0001812727 2022-01-31 0001812727 RELI:SeriesAConvertiblePreferredStockMember 2021-12-31 0001812727 RELI:SeriesAConvertiblePreferredStockMember 2022-03-31 0001812727 us-gaap:SeriesBPreferredStockMember 2021-12-31 0001812727 2021-02-01 2021-02-28 0001812727 RELI:RelianceGlobalHoldingsLLCMember 2021-02-01 2021-02-28 0001812727 RELI:RelianceGlobalHoldingsLLCMember 2021-02-28 0001812727 RELI:JPKushAndAssociatesIncMember 2021-04-29 2021-05-31 0001812727 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2022-01-01 2022-01-31 0001812727 RELI:MedigapAcquisitionMember 2022-01-01 2022-01-31 0001812727 RELI:SeriesAWarrantMember 2022-01-01 2022-01-31 0001812727 RELI:SeriesAWarrantMember 2022-01-31 0001812727 us-gaap:CommonStockMember 2022-01-01 2022-01-31 0001812727 us-gaap:CommonStockMember 2022-03-01 2022-03-31 0001812727 RELI:TwoThousandNineteenEquityIncentivePlanMember 2019-12-31 0001812727 RELI:TwoThousandNineteenEquityIncentivePlanMember 2022-03-31 0001812727 RELI:ServiceProviderMember 2022-01-01 2022-03-31 0001812727 RELI:EmployeesDirectorsAndConsultantsMember 2022-01-01 2022-03-31 0001812727 RELI:TwoThousandNineteenEquityIncentivePlanMember RELI:ServiceProviderMember 2021-01-01 2021-03-31 0001812727 RELI:EmployeesDirectorsAndConsultantsMember 2021-01-01 2021-03-31 0001812727 RELI:SeriesAWarrantMember 2022-03-31 0001812727 RELI:SeriesAWarrantMember 2022-01-01 2022-03-31 0001812727 us-gaap:WarrantMember 2022-01-01 2022-01-31 0001812727 RELI:SeriesAWarrantsMember 2022-03-31 0001812727 RELI:SeriesCPrepaidWarrantsMember 2022-01-31 0001812727 RELI:SeriesCPrepaidWarrantsMember us-gaap:CommonStockMember 2022-01-31 0001812727 RELI:SeriesDPrepaidWarrantsMember 2022-01-31 0001812727 RELI:ThreeEmployeesMember 2022-01-01 2022-03-31 0001812727 RELI:TwoEmployeesMember 2022-01-01 2022-03-31 0001812727 2020-01-01 2020-12-31 0001812727 srt:MinimumMember 2022-03-31 0001812727 srt:MaximumMember 2022-03-31 0001812727 srt:MinimumMember 2021-03-31 0001812727 srt:MaximumMember 2021-03-31 0001812727 srt:MinimumMember 2021-01-01 2021-03-31 0001812727 srt:MaximumMember 2021-01-01 2021-03-31 0001812727 RELI:CommonStockOptionMember 2022-01-01 2022-03-31 0001812727 RELI:CommonStockOptionMember 2021-01-01 2021-03-31 0001812727 RELI:SeriesAWarrantMember 2022-01-01 2022-03-31 0001812727 RELI:SeriesAWarrantMember 2021-01-01 2021-03-31 0001812727 RELI:UnvestedStockAwardsMember 2022-01-01 2022-03-31 0001812727 RELI:UnvestedStockAwardsMember 2021-01-01 2021-03-31 0001812727 RELI:ConversionSeriesBPreferredStockMember 2022-01-01 2022-03-31 0001812727 RELI:ConversionSeriesBPreferredStockMember 2021-01-01 2021-03-31 0001812727 RELI:CommercialSolutionsOfInsuranceAgencyLLCMember 2021-12-31 0001812727 RELI:FortmanInsuranceAgencyLLCMember 2021-12-31 0001812727 RELI:SouthwesternMontanaInsuranceCenterIncMember 2021-12-31 0001812727 RELI:AltruisBenefitsConsultantsIncMember 2021-12-31 0001812727 RELI:JPKushAndAssociatesIncMember 2021-12-31 0001812727 RELI:CommercialSolutionsOfInsuranceAgencyLLCMember 2022-01-01 2022-03-31 0001812727 RELI:FortmanInsuranceAgencyLLCMember 2022-01-01 2022-03-31 0001812727 RELI:SouthwesternMontanaInsuranceCenterIncMember 2022-01-01 2022-03-31 0001812727 RELI:AltruisBenefitsConsultantsIncMember 2022-01-01 2022-03-31 0001812727 RELI:CommercialSolutionsOfInsuranceAgencyLLCMember 2022-03-31 0001812727 RELI:FortmanInsuranceAgencyLLCMember 2022-03-31 0001812727 RELI:SouthwesternMontanaInsuranceCenterIncMember 2022-03-31 0001812727 RELI:AltruisBenefitsConsultantsIncMember 2022-03-31 0001812727 RELI:CommercialSolutionsOfInsuranceAgencyLLCMember 2020-12-31 0001812727 RELI:FortmanInsuranceAgencyLLCMember 2020-12-31 0001812727 RELI:SouthwesternMontanaInsuranceCenterIncMember 2020-12-31 0001812727 RELI:AltruisBenefitsConsultantsIncMember 2020-12-31 0001812727 RELI:JPKushAndAssociatesIncMember 2020-12-31 0001812727 RELI:CommercialSolutionsOfInsuranceAgencyLLCMember 2021-01-01 2021-12-31 0001812727 RELI:FortmanInsuranceAgencyLLCMember 2021-01-01 2021-12-31 0001812727 RELI:SouthwesternMontanaInsuranceCenterIncMember 2021-01-01 2021-12-31 0001812727 RELI:AltruisBenefitsConsultantsIncMember 2021-01-01 2021-12-31 0001812727 RELI:JPKushAndAssociatesIncMember 2021-01-01 2021-12-31 0001812727 RELI:RelianceHoldingsMember 2022-03-31 0001812727 RELI:RelianceHoldingsMember 2021-12-31 0001812727 us-gaap:SubsequentEventMember RELI:APAMember RELI:BarraAndAssociatesLLCMember 2022-04-25 2022-04-26 0001812727 us-gaap:SubsequentEventMember RELI:APAMember RELI:BarraAndAssociatesLLCMember RELI:PaidAtClosingMember 2022-04-25 2022-04-26 0001812727 us-gaap:SubsequentEventMember RELI:APAMember RELI:BarraAndAssociatesLLCMember RELI:PayableInSixMonthsMember 2022-04-25 2022-04-26 0001812727 us-gaap:SubsequentEventMember RELI:APAMember RELI:BarraAndAssociatesLLCMember RELI:PayableOverTwoYearsMember 2022-04-25 2022-04-26 0001812727 us-gaap:SubsequentEventMember RELI:APAMember RELI:BarraAndAssociatesLLCMember 2022-04-26 0001812727 us-gaap:SubsequentEventMember RELI:APAMember RELI:BarraAndAssociatesLLCMember RELI:OakStreetLendingMember 2022-04-25 2022-04-26 0001812727 us-gaap:SubsequentEventMember RELI:OakStreetLendingMember RELI:TermLoanMember 2022-04-26 0001812727 RELI:TermLoanMember RELI:OakStreetFundingLLCMember us-gaap:SubsequentEventMember 2022-04-25 2022-04-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares RELI:Policy RELI:Agent xbrli:pure

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q/A

(Amendment No. 1)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2022

or

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission File Number: 001-40020

RELIANCE GLOBAL GROUP, INC.

(Exact name of registrant as specified in its charter)

Florida

(State or other jurisdiction of incorporation or organization)

46-3390293

I.R.S. Employer Identification Number

300 Blvd. of the Americas, Suite 105 Lakewood, NJ 08701

(Address of principal executive offices) (Zip Code)

732-380-4600

(Registrant’s telephone number, including area code)

N/A

(Former name, former address, and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class |  | Trading Symbol(s) |  | Name of each exchange on which registered
Common Stock |  | RELI |  | The Nasdaq Capital Market
Series A Warrants |  | RELIW |  | Nasdaq Capital Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company, in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ | Accelerated filer ☐
Non-accelerated filer ☒ | Smaller reporting company ☒
Emerging growth company ☐ |

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2 of the Act).

Yes ☐ No ☒

At May 16, 2022 the registrant had 755,807 shares of common stock, par value $0.086 per share, outstanding (after giving effect to the 1-for-15 reverse stock split that became effective on February 23, 2023).

EXPLANATORY NOTE

Reliance Global Group, Inc. (the “Company”) filed its Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, with the Securities and Exchange Commission (“SEC”) on May 16, 2022 (the “Original Form 10-Q”). This Amendment No. 1 on Form 10-Q/A (“Amendment No. 1” or “Form 10-Q/A”) is being filed to:

(i) | reflect the restatement of earnings per share (“EPS”) information (the “Restatement”) in the condensed consolidated statements of operations for the three months ended March 31, 2022;
(ii) | insert additional disclosure relating to the Restatement to Note 2;
(iii) | replace Note 12 from the Original Form 10-Q in its entirety as a result of the Restatement;
(iv) | revise share and per share information throughout the Form 10-Q/A to give effect to the 1-for-15 reverse stock split that became effective on February 23, 2023 (the “Reverse Split”);
(v) | revise Part I, Item 4 to indicate that the Company’s disclosure controls and procedures were not effective as of March 31, 2022;
(vi) | replace the exhibit index contained in Item 6 in its entirety;
(vii) | provide current dated certifications;
(viii) | correct certain immaterial errors on the cover sheet to the Form 10-Q/A.

The Restatement is due to the Company performing an evaluation of its accounting in connection with the calculation of its basic and diluted EPS for the three months ended March 31, 2022, and identification of errors in such calculation for the prior period. On May 12, 2023, management concluded its evaluation and determined that the identified errors require the filing of Amendment No. 1, as further discussed in Notes 2 and 12 to the unaudited condensed consolidated financial statements included in this Form 10-Q/A.

The following items have been amended in this Amendment No. 1:

| ● | Part I — Item 1. Financial Statements
| ● | Part I – Item 4. Controls and Procedures
| ● | Part II – Item 6. Exhibits

Except as described above, no other changes have been made to the Original Form 10-Q, and Amendment No. 1 does not modify, amend or update in any way revenue, expenses, net income (loss), or any of the financial or other information contained in the Original Form 10-Q. Amendment No. 1 does not reflect events that may have occurred subsequent to the filing date of the Original Form 10-Q other than adjusting, in the Items amended herein, common stock share and price per share information for the 1-for-15 reverse stock split that became effective February 23, 2023.

TABLE OF CONTENTS

PART I | 1
Item 1. Financial Statements | 1
Item 4. Controls and Procedures | 29
PART II | 30
Item 6. Exhibits | 30
Signatures | 31

PART I

Item 1. Financial Statements

Reliance Global Group, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

(Unaudited)

|  |  | March 31, 2022 |  |  |  | December 31, 2021 |
|  | March 31, 2022 |  |  | December 31, 2021 |
Assets |  |  |  |  |  |  |  |
Current assets: |  |  |  |  |  |  |  |
Cash |  | $ | 5,491,407 |  |  | $ | 4,136,180 |
Restricted cash |  |  | 484,351 |  |  |  | 484,542 |
Accounts receivable |  |  | 1,173,383 |  |  |  | 1,024,831 |
Accounts receivable, related parties |  |  | 1,642 |  |  |  | 7,131 |
Other receivables |  |  | 7,336 |  |  |  | - |
Prepaid expense and other current assets |  |  | 111,639 |  |  |  | 2,328,817 |
Total current assets |  |  | 7,269,758 |  |  |  | 7,981,501 |
Property and equipment, net |  |  | 147,140 |  |  |  | 130,359 |
Right-of-use assets |  |  | 1,287,636 |  |  |  | 1,067,734 |
Investment in NSURE, Inc. |  |  | 1,350,000 |  |  |  | 1,350,000 |
Intangibles, net |  |  | 11,895,223 |  |  |  | 7,078,900 |
Goodwill |  |  | 29,249,285 |  |  |  | 10,050,277 |
Other non-current assets |  |  | 69,784 |  |  |  | 16,792 |
Total assets |  | $ | 51,268,826 |  |  | $ | 27,675,563 |
Liabilities and stockholders’ equity (deficit) |  |  |  |  |  |  |  |
Current liabilities: |  |  |  |  |  |  |  |
Accounts payable and other accrued liabilities |  | $ | 1,043,117 |  |  | $ | 2,759,160 |
Chargeback reserve |  |  | 1,585,435 |  |  |  | - |
Other payables |  |  | 80,033 |  |  |  | 81,500 |
Current portion of long-term debt |  |  | 918,073 |  |  |  | 913,920 |
Current portion of leases payable |  |  | 434,045 |  |  |  | 276,009 |
Earn-out liability, current portion |  |  | 3,774,411 |  |  |  | 3,297,855 |
Warrant commitment |  |  | - |  |  |  | 37,652,808 |
Total current liabilities |  |  | 7,835,114 |  |  |  | 44,981,252 |
Loans payable, related parties, less current portion |  |  | 342,996 |  |  |  | 353,766 |
Long term debt, less current portion |  |  | 6,860,467 |  |  |  | 7,085,325 |
Leases payable, less current portion |  |  | 871,234 |  |  |  | 805,326 |
Earn-out liability, less current portion |  |  | 446,538 |  |  |  | 516,023 |
Warrant liabilities |  |  | 23,660,144 |  |  |  | - |
Total liabilities |  |  | 40,016,493 |  |  |  | 53,741,692 |
Stockholders’ equity (deficit): |  |  |  |  |  |  |  |
Preferred stock, $0.086 par value; 750,000,000 shares authorized and 9,076 and 0 issued and outstanding as of March 31, 2022 and December 31, 2021, respectively |  |  | 781 |  |  |  | - |
Common stock, $0.086 par value; 133,333,333 shares authorized and 755,806 and 730,407 issued and outstanding as of March 31, 2022 and December 31, 2021, respectively |  |  | 64,999 |  |  |  | 62,815 |
Additional paid-in capital |  |  | 35,304,698 |  |  |  | 27,329,201 |
Stock subscription receivable |  |  | - |  |  |  | (20,000,000 | )
Accumulated deficit |  |  | (24,118,145 | ) |  |  | (33,458,145 | )
Total stockholders’ equity (deficit) |  |  | 11,252,333 |  |  |  | (26,066,129 | )
Total liabilities and stockholders’ equity |  | $ | 51,268,826 |  |  | $ | 27,675,563 |

The accompanying notes are an integral part of these condensed consolidated financial statements

1

Reliance Global Group, Inc. and Subsidiaries

Condensed Consolidated Statements of Operations

(Unaudited)

|  |  | March 31, 2022 |  |  |  | March 31, 2021 |
|  | March 31, 2022 |  |  | March 31, 2021 |
Revenue |  |  |  |  |  |  |  |
Commission income |  | $ | 4,235,781 |  |  | $ | 2,323,730 |
Total revenue |  |  | 4,235,781 |  |  |  | 2,323,730 |
Operating expenses |  |  |  |  |  |  |  |
Commission expense |  |  | 904,156 |  |  |  | 529,472 |
Salaries and wages |  |  | 2,082,175 |  |  |  | 918,545 |
General and administrative expenses |  |  | 2,453,070 |  |  |  | 1,004,401 |
Marketing and advertising |  |  | 587,022 |  |  |  | 23,079 |
Depreciation and amortization |  |  | 607,525 |  |  |  | 333,088 |
Total operating expenses |  |  | 6,633,948 |  |  |  | 2,808,585 |
Loss from operations |  |  | (2,398,167 | ) |  |  | (484,855 | )
Other income (expense) |  |  |  |  |  |  |  |
Other expense, net |  |  | (107,797 | ) |  |  | (129,071 | )
Recognition and change in fair value of warrant liabilities |  |  | 11,845,964 |  |  |  | - |
Total other income (expense) |  |  | 11,738,167 |  |  |  | (129,071 | )
Net income (loss) |  | $ | 9,340,000 |  |  | $ | (613,926 | )
Basic earnings (loss) per share |  | $ | 2.46 |  |  | $ | (1.22 | )
Diluted earnings (loss) per share |  | $ | (9.69 | ) |  | $ | (1.22 | )
Weighted average number of shares outstanding - Basic |  |  | 980,569 |  |  |  | 502,825 |
Weighted average number of shares outstanding - Diluted |  |  | 1,195,480 |  |  |  | 502,825 |

The accompanying notes are an integral part of these condensed consolidated financial statements

2

Reliance Global Group, Inc. and Subsidiaries

Condensed Consolidated Statements of Stockholders’ Equity (Deficit)

(Unaudited)

|  | Shares |  |  |  | Amount |  |  | Shares |  |  |  | Amount |  |  | Shares |  |  |  | Amount |  |  |  | capital |  |  |  | Receivable |  |  |  | Deficit |  |  |  | Total |
|  | Reliance Global Group, Inc. |
|  | Preferred stock |  |  | Common stock |  |  | Common stock issuable |  |  | Additional paid-in |  |  | Subscription |  |  | Accumulated |  |  |  |
|  | Shares |  |  | Amount |  |  | Shares |  |  | Amount |  |  | Shares |  |  | Amount |  |  | capital |  |  | Receivable |  |  | Deficit |  |  | Total |
Balance, December 31, 2021 |  |  | - |  |  | $ | - |  |  |  | 730,407 |  |  | $ | 62,815 |  |  |  | - |  |  | $ | - |  |  | $ | 27,329,201 |  |  | $ | (20,000,000 | ) |  | $ | (33,458,145 | ) |  | $ | (26,066,129 | )
Share based compensation |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 739,960 |  |  |  | - |  |  |  | - |  |  |  | 739,960 |
Shares issued due to private placement |  |  | 9,076 |  |  |  | 781 |  |  |  | 178,059 |  |  |  | 15,313 |  |  |  | - |  |  |  | - |  |  |  | (16,043 | ) |  |  | 20,000,000 |  |  |  | - |  |  |  | 20,000,051 |
Shares issued pursuant to acquisition of Medigap |  |  | - |  |  |  | - |  |  |  | 40,402 |  |  |  | 3,475 |  |  |  | - |  |  |  | - |  |  |  | 4,759,976 |  |  |  | - |  |  |  | - |  |  |  | 4,763,451 |
Exercise of Series A warrants |  |  | - |  |  |  | - |  |  |  | 25,000 |  |  |  | 2,150 |  |  |  | - |  |  |  | - |  |  |  | 2,472,850 |  |  |  | - |  |  |  | - |  |  |  | 2,475,000 |
Issuance of prefunded Series C Warrants in exchange for common shares |  |  | - |  |  |  | - |  |  |  | (218,462 | ) |  |  | (18,788 | ) |  |  | - |  |  |  | - |  |  |  | 18,788 |  |  |  | - |  |  |  | - |  |  |  | - |
Shares issued for vested stock awards |  |  | - |  |  |  | - |  |  |  | 400 |  |  |  | 34 |  |  |  | - |  |  |  | - |  |  |  | (34 | ) |  |  | - |  |  |  | - |  |  |  | - |
Net Income |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 9,340,000 |  |  |  | 9,340,000 |
Balance, March 31, 2022 |  |  | 9,076 |  |  | $ | 781 |  |  |  | 755,806 |  |  | $ | 64,999 |  |  |  | - |  |  | $ | - |  |  | $ | 35,304,698 |  |  | $ | - |  |  | $ | (24,118,145 | ) |  | $ | 11,252,333 |

The accompanying notes are an integral part of these condensed consolidated financial statements

3

Reliance Global Group, Inc. and Subsidiaries

Condensed Consolidated Statements of Stockholders’ Equity (Deficit)

(Unaudited)

|  | Shares |  |  |  | Amount |  |  | Shares |  |  |  | Amount |  |  | Shares |  |  |  | Amount |  |  |  | in capital |  |  |  | Deficit |  |  |  | Total |
|  | Reliance Global Group, Inc. |
|  | Preferred stock |  |  | Common stock |  |  | Common stock issuable |  |  | Additional paid- |  |  | Accumulated |  |  |  |
|  | Shares |  |  | Amount |  |  | Shares |  |  | Amount |  |  | Shares |  |  | Amount |  |  | in capital |  |  | Deficit |  |  | Total |
Balance, December 31, 2020 |  |  | 395,640 |  |  | $ | 33,912 |  |  |  | 282,735 |  |  | $ | 24,315 |  |  |  | 1,556 |  |  | $ | 340,000 |  |  | $ | 11,898,441 |  |  | $ | (12,359,680 | ) |  | $ | (63,012 | )
Balance |  |  | 395,640 |  |  | $ | 33,912 |  |  |  | 282,735 |  |  | $ | 24,315 |  |  |  | 1,556 |  |  | $ | 340,000 |  |  | $ | 11,898,441 |  |  | $ | (12,359,680 | ) |  | $ | (63,012 | )
Share based compensation |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 246,966 |  |  |  | - |  |  |  | 246,966 |
Shares issued for services |  |  | - |  |  |  | - |  |  |  | 1,000 |  |  |  | 86 |  |  |  | - |  |  |  | - |  |  |  | 90,964 |  |  |  | - |  |  |  | 91,050 |
Shares issued due to public offering, net of offering costs of $1,672,852 |  |  | - |  |  |  | - |  |  |  | 120,000 |  |  |  | 10,320 |  |  |  | - |  |  |  | - |  |  |  | 9,098,828 |  |  |  | - |  |  |  | 9,109,148 |
Shares issued due to private placement |  |  | - |  |  |  | - |  |  |  | 120,000 |  |  |  | 10,320 |  |  |  | - |  |  |  | - |  |  |  | 9,098,828 |  |  |  | - |  |  |  | 9,109,148 |
Over-allotment shares from offering, net of offering costs of $250,928 |  |  | - |  |  |  | - |  |  |  | 18,000 |  |  |  | 1,548 |  |  |  | - |  |  |  | - |  |  |  | 1,364,825 |  |  |  | - |  |  |  | 1,366,373 |
Warrants sold during public offering at quoted price |  |  | - |  |  |  | - |  |  |  | - |  |  |  |  |  |  |  | - |  |  |  | - |  |  |  | 20,700 |  |  |  | - |  |  |  | 20,700 |
Shares issued due to conversion of preferred stock |  |  | (394,493 | ) |  |  | (33,812 | ) |  |  | 262,995 |  |  |  | 22,618 |  |  |  | - |  |  |  | - |  |  |  | 11,194 |  |  |  | - |  |  |  | - |
Shares issued due to conversion of debt |  |  | - |  |  |  | - |  |  |  | 42,222 |  |  |  | 3,631 |  |  |  | - |  |  |  | - |  |  |  | 3,796,369 |  |  |  | - |  |  |  | 3,800,000 |
Rounding shares related to initial public offering |  |  | - |  |  |  | - |  |  |  | 126 |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Shares issued pursuant to software purchase |  |  | - |  |  |  | - |  |  |  | 1,556 |  |  |  | 134 |  |  |  | (1,556 | ) |  |  | (340,000 | ) |  |  | 339,866 |  |  |  | - |  |  |  | 0 |
Net loss |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (613,926 | ) |  |  | (613,926 | )
Net income (loss) |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (613,926 | ) |  |  | (613,926 | )
Balance, March 31, 2021 |  |  | 1,147 |  |  | $ | 100 |  |  |  | 728,634 |  |  | $ | 62,652 |  |  |  | - |  |  | $ | - |  |  | $ | 26,868,153 |  |  | $ | (12,973,606 | ) |  | $ | 13,957,299 |
Balance |  |  | 1,147 |  |  | $ | 100 |  |  |  | 728,634 |  |  | $ | 62,652 |  |  |  | - |  |  | $ | - |  |  | $ | 26,868,153 |  |  | $ | (12,973,606 | ) |  | $ | 13,957,299 |

The accompanying notes are an integral part of these condensed consolidated financial statements

4

Reliance Global Group, Inc. and Subsidiaries and Predecessor

Condensed Consolidated Statements of Cash Flows

(Unaudited)

|  |  | March 31, 2022 |  |  |  | March 31, 2021 |
Cash flows from operating activities: |  |  |  |  |  |  |  |
Net income (loss) |  | $ | 9,340,000 |  |  | $ | (613,926 | )
Adjustment to reconcile net income to net cash (used) provided by operating activities: |  |  |  |  |  |  |  |
Depreciation and amortization |  |  | 607,528 |  |  |  | 333,087 |
Amortization of debt issuance costs and accretion of debt discount |  |  | 6,467 |  |  |  | 5,722 |
Non-cash lease expense |  |  | 4,042 |  |  |  | (4,704 | )
Stock compensation expense |  |  | 739,960 |  |  |  | 352,299 |
Earn-out fair value and write-off adjustments |  |  | 407,071 |  |  |  | - |
Recognition and change in fair value of warrant liabilities |  |  | (11,845,964 | ) |  |  | - |
Change in operating assets and liabilities: |  |  |  |  |  |  |  |
Accounts payables and other accrued liabilities |  |  | (1,715,666 | ) |  |  | (893,505 | )
Accounts receivable |  |  | (148,552 | ) |  |  | 181,556 |
Accounts receivable, related parties |  |  | 5,489 |  |  |  | (7,131 | )
Other receivables |  |  | (7,336 | ) |  |  | - |
Other payables |  |  | (1,467 | ) |  |  | - |
Charge back reserve |  |  | 100,962 |  |  |  |  |
Other non-current assets |  |  | (52,992 | ) |  |  | - |
Prepaid expense and other current assets |  |  | 2,217,178 |  |  |  | - |
Net cash used in operating activities |  |  | (343,280 | ) |  |  | (646,602 | )
Cash flows from investing activities: |  |  |  |  |  |  |  |
Purchase of property and equipment |  |  | (4,108 | ) |  |  | - |
Acquisition of business, net of cash acquired |  |  | (18,138,750 | ) |  |  | - |
Purchase of intangibles |  |  | (249,235 | ) |  |  | - |
Net cash used in investing activities |  |  | (18,392,093 | ) |  |  | - |

The accompanying notes are an integral part of these condensed consolidated financial statements

5

Reliance Global Group, Inc. and Subsidiaries

Condensed Consolidated Statements of Cash Flows

(Unaudited)

Cash flows from financing activities: |  |  |  |  |  |  |  |
Principal repayments of debt |  |  | (227,172 | ) |  |  | (213,994 | )
Proceeds from loans payable, related parties |  |  | - |  |  |  | 177,824 |
Payments of loans payable, related parties |  |  | (10,770 | ) |  |  | (310,771 | )
Proceeds from exercise of warrants into common stock |  |  | 2,475,000 |  |  |  | - |
Net proceeds from private placement issuance of shares and warrants |  |  | 17,853,351 |  |  |  | - |
Issuance of common stock |  |  | - |  |  |  | 10,481,938 |
Net cash provided by financing activities |  |  | 20,090,409 |  |  |  | 10,134,997 |
Net increase in cash and restricted cash |  |  | 1,355,036 |  |  |  | 9,488,395 |
Cash and restricted cash at beginning of period |  |  | 4,620,722 |  |  |  | 529,581 |
Cash and restricted cash at end of period |  | $ | 5,975,758 |  |  | $ | 10,017,976 |
Supplemental disclosure of cash and non-cash investing and financing transactions: |  |  |  |  |  |  |  |
Issuance of Series D Warrants |  | $ | 6,930,335 |  |  | $ | - |
Issuance of placement agent warrants |  | $ | 1,525,923 |  |  |  | - |
Conversion of common stock into Series C Warrants |  | $ | 281,815 |  |  | $ | - |
Conversion of preferred stock into common stock |  | $ | - |  |  | $ | 339,264 |
Cash paid for interest |  | $ | 105,447 |  |  | $ | 116,830 |
Conversion of debt into equity |  | $ | - |  |  | $ | 3,800,000 |
Common stock issued pursuant to acquisition |  | $ | 4,763,451 |  |  | $ | - |
Common stock issued in lieu of services |  | $ | - |  |  | $ | 91,050 |
Issuance of common stock pursuant to the purchase of software |  | $ | - |  |  | $ | 340,000 |

The accompanying notes are an integral part of these condensed consolidated financial statements

6

Reliance Global Group, Inc. and Subsidiaries

Notes to the Condensed Consolidated Financial Statements

NOTE 1. ORGANIZATION AND DESCRIPTION OF BUSINESS

Reliance Global Group, Inc. (formerly known as Ethos Media Network, Inc.) (“RELI”, “Reliance”, or the “Company”) was incorporated in Florida on August 2, 2013. In September 2018, Reliance Global Holdings, LLC (“Reliance Holdings”, or “Parent Company”), a related party acquired control of the Company. Ethos Media Network, Inc. was then renamed on October 18, 2018.

On May 1, 2021, the Company acquired J.P. Kush and Associates, Inc. (“Kush”), an independent healthcare insurance agency (See Note 3).

On January 10, 2022, the Company acquired Medigap Healthcare Insurance Company, LLC (“Medigap”), an independent healthcare agency (see Note 3)

NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation and Principles of Consolidation

The accompanying unaudited condensed consolidated financial statements included herein have been prepared by the Company in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying unaudited condensed consolidated financial statements include the accounting of Reliance Global Group, Inc., and its wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2021 included in the Company’s annual report on Form 10-K.

Restatement of Previously Issued Financial Statements

Subsequent to the Company’s filing of its Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, with the Securities and Exchange Commission on May 16, 2022, the Company performed an evaluation of its accounting in connection with the calculation of its basic Earnings Per Share (“EPS”) and diluted EPS for the three months ended March 31, 2022, which concluded on May 12, 2023, and identified errors in such calculation. The errors resulted from improper application of sequencing rules, a miscalculation of the numerator used in the determination of diluted EPS, and a miscalculation of the denominator used in the determination of weighted average shares outstanding for both basic EPS and diluted EPS, and the Company determined that the errors required adjustments of the previously issued financial statements for the quarter ended March 31, 2022. Accordingly, the Company restates its consolidated financial statements for the identified periods in this Form 10-Q/A as outlined further below and in Note 12 Earnings (Loss) Per Share.

The following table sets forth the effects of the adjustments on affected items within the Company’s previously reported consolidated statements of operations for the three months ended March 31, 2022, and includes an increase to basic earnings per share in the amount of $0.51, an increase to diluted loss per share in the amount of $3.39, a decrease to weighted average number of shares outstanding – basic of 234,447 shares, and a decrease to weighted average number of shares outstanding - diluted of 377,805 shares.

SCHEDULE OF PREVIOUSLY REPORTED CONSOLIDATED STATEMENTS OF OPERATIONS

|  | Three Months Ended March 31, 2022 |
|  | As Reported |  |  | Adjustment |  |  | As Corrected |
Basic earnings (loss) per share |  |  | 1.95 |  |  |  | 0.51 |  |  |  | 2.46 |
Diluted earnings (loss) per share |  |  | (6.30 | ) |  |  | (3.39 | ) |  |  | (9.69 | )
Weighted average number of shares outstanding – Basic |  |  | 1,215,016 |  |  |  | (234,447 | ) |  |  | 980,569 |
Weighted average number of shares outstanding - Diluted |  |  | 1,573,285 |  |  |  | (377,805 | ) |  |  | 1,195,480 |

Additionally, please refer to Note 12. Earnings (Loss) Per Share, where the Company has corrected and replaced that Note in its entirety.

Liquidity

As of March 31, 2022, the Company’s reported cash and restricted cash aggregated balance was approximately $5,976,000, current assets were approximately $7,270,000, while current liabilities were approximately $7,835,000. As of March 31, 2022, the Company had a working capital deficit of approximately $565,000 and stockholders’ equity of approximately $11,252,000. For the three months ended March 31, 2022, the Company reported loss from operations of approximately $2,398,000, a non-cash, non-operating gain on the recognition and change in fair value of warrant liabilities of approximately $11,846,000, resulting in an overall net income of approximately $9,340,000. The Company reported negative cash flows from operations of approximately $343,000. The Company completed a capital offering in January 2022 that raised net proceeds of approximately $17,853,352. Management believes the company’s financial position and its ability to raise capital to be reasonable and sufficient, providing ample liquidity for the foreseeable future.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures in the financial statements and accompanying notes. Management bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. Actual results could differ materially from those estimates.

Cash

Cash consists of checking accounts. The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.

7

Restricted Cash

Restricted cash includes cash pledged as collateral to secure obligations and/or all cash whose use is otherwise limited by contractual provisions.

The reconciliation of cash and restricted cash reported within the applicable balance sheet accounts that sum to the total of cash and restricted cash presented in the statement of cash flows is as follows:

SCHEDULE OF RESTRICTED CASH IN STATEMENT OF CASH FLOW

|  | March 31, 2022 |  |  | March 31, 2021 |
Cash |  | $ | 5,491,407 |  |  | $ | 9,432,070 |
Restricted cash |  |  | 484,351 |  |  |  | 585,906 |
Total cash and restricted cash |  | $ | 5,975,758 |  |  | $ | 10,017,976 |

Property and Equipment

Property and equipment is stated at cost, less accumulated depreciation. Depreciation is recognized over an asset’s estimated useful life using the straight-line method beginning on the date an asset is placed in service. The Company regularly evaluates the estimated remaining useful lives of the Company’s property and equipment to determine whether events or changes in circumstances warrant a revision to the remaining period of depreciation. Maintenance and repairs are charged to expense as incurred. Estimated useful lives of the Company’s Property and Equipment are as follows:

SCHEDULE OF PROPERTY AND EQUIPMENT

| Useful Life (in years)
Computer equipment |  | 5
Office equipment and furniture |  | 7
Leasehold improvements |  | Shorter of the useful life or the lease term

Fair Value of Financial Instruments

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The accounting guidance includes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The three levels of the fair value hierarchy are as follows:

Level 1 — Observable inputs that reflect quoted prices (unadjusted) in active markets for identical assets and liabilities;

Level 2 — Inputs other than quoted prices in active markets for identical assets and liabilities that are observable either directly or indirectly for substantially the full term of the asset or liability; and

Level 3 — Unobservable inputs for the asset or liability, which include management’s own assumption about the assumptions market participants would use in pricing the asset or liability, including assumptions about risk.

As of March 31, 2022 and December 31, 2021 respectively, the Company’s balance sheet includes certain financial instruments, including cash, notes receivables, accounts payable, and short and long-term debt. The carrying amounts of current assets and current liabilities approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization. The carrying amounts of long-term debt approximate their fair value as the variable interest rates are based on a market index.

The Company’s Warrant Commitment and warrant liabilities (“Warrant Liabilities”) (see Note 13, Commitments and Contingencies) represent liability-classified derivative financial instruments recorded at fair value on a recurring basis. The fair value includes significant inputs unobservable in the market and thus are considered Level 3. The Company measures fair value of Warrant Liabilities at issuance date and subsequently at the balance sheet date, using a binomial option pricing model. The significant inputs used in estimating fair value not adjusting for any reverse stock splits, include the fair value of the underlying stock, expected term, risk free interest rate, and expected volatility, as follows:

SCHEDULE OF FAIR VALUE OF WARRANT COMMITMENT

|  |  | March 31, 2022 |  |  |  | December 31, 2021 |
Stock price |  | $ | 4.31 |  |  | $ | 6.44 |
Volatility |  |  | 90 | % |  |  | 90 | %
Time to expiry |  |  | 5 |  |  |  | 5 |
Dividend yield |  |  | 0 | % |  |  | 0 | %
Risk free rate |  |  | 2.4 | % |  |  | 1.10 | %
Warrant liability, measurement input |  |  |  |  |  |  |  |

The following reconciles the fair values of the liability classified warrants:

SCHEDULE OF RECONCILES WARRANT COMMITMENT

|  |  | Series B Warrant Commitment |  |  |  | Series B warrant liabilities |  |  |  | Placement agent warrants |  |  | Total |
|  | March 31, 2022 |
|  | Series B Warrant Commitment |  |  | Series B warrant liabilities |  |  | Placement agent warrants |  |  | Total |
Beginning balance |  | $ | 37,652,808 |  |  | $ | - |  |  | $ | - |  |  | $ | 37,652,808 |
Initial recognition |  |  | - |  |  |  | 55,061,119 |  |  |  | 1,525,923 |  |  |  | 56,587,042 |
Unrealized (gain) loss |  |  | 17,408,311 |  |  |  | (31,980,437 | ) |  |  | (946,461 | ) |  |  | (15,518,587 | )
Warrants exercised or transferred |  |  | (55,061,119 | ) |  |  |  |  |  |  |  |  |  |  | (55,061,119 | )
Ending balance |  | $ | - |  |  | $ | 23,080,682 |  |  | $ | 579,462 |  |  | $ | 23,660,144 |

|  |  | Series B Warrant Commitment |  |  |  | Total |
|  | December 31, 2021 |
|  | Series B Warrant Commitment |  |  | Total |
Beginning balance |  | $ | - |  |  | $ | - |
Initial recognition |  |  | 20,244,497 |  |  |  | 20,244,497 |
Unrealized (gain) loss |  |  | 17,408,311 |  |  |  | 17,408,311 |
Warrants exercised or transferred |  |  | - |  |  |  | - |
Ending balance |  | $ | 37,652,808 |  |  | $ | 37,652,808 |

The Company’s contingent accrued earn-out business acquisition consideration liabilities are considered Level 3 fair value liability instruments requiring period fair value assessments. These contingent consideration liabilities were recorded at fair value on the acquisition date and are re-measured quarterly based on the then assessed fair value and adjusted if necessary. The increases or decreases in the fair value of contingent consideration can result from changes in anticipated revenue levels and changes in assumed discount periods and rates. As the fair value measure is based on significant inputs that are unobservable in the market, they are categorized as Level 3.

As of March 31, 2022 and December 31, 2021 respectively, the earn-out liability account balance as reported in the condensed consolidated balance sheets is $4,220,949 and $3,813,878. At March 31, 2022 and December 31, 2021, the current portion of the earn-out liability is $3,774,411 and $3,297,855, respectively, and the non-current earn out liability, net of current portion was $446,538 and $516,023, respectively. In fair valuing these instruments, the income valuation approach is applied and key valuation inputs include contingent payment arrangement terms, projected revenues and cash flows, rate of return, and probability assessments. Undiscounted remaining earn out payments are approximately $4,345,000 as of March 31, 2022.

8

For the Company’s earn-out liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3), the following table provides a reconciliation of the beginning and ending balances for each category therein, and gains or losses recognized during the period ended March 31, 2022 and December 31, 2021:

SCHEDULE OF GAIN OR LOSSES RECOGNIZED FAIR VALUE

|  |  | March 31, 2022 |  |  |  | December 31, 2021 |
Beginning balance - January 1 |  | $ | 3,813,878 |  |  | $ | 2,931,418 |
Acquisitions and Settlements: |  |  | - |  |  |  | - |
JP Kush Acquisition |  |  | - |  |  |  | 1,694,166 |
CCS Write-off |  |  | - |  |  |  | (81,368 | )
Altruis partial settlement |  |  | - |  |  |  | (452,236 | )
|  |  | - |  |  |  | - |
Period adjustments: |  |  |  |  |  |  |  |
Fair value changes and accretion included in earnings* |  |  | 407,071 |  |  |  | (278,102 | )
Ending balance |  | $ | 4,220,949 |  |  | $ | 3,813,878 |

* | Recorded as a reduction to general and administrative expenses

Quantitative Information about Level 3 Fair Value Measurements

Significant unobservable inputs used in the earn-out fair value measurements of the Company’s contingent consideration liabilities designated as Level 3 are as follows:

SCHEDULE OF FAIR VALUE MEASUREMENTS

|  | March 31, 2022 |  |  | December 31, 2021 |
Fair value |  | $ | 4,220,949 |  |  | $ | 3,813,878 |
Valuation technique |  |  | Discounted cash flow |  |  |  | Discounted cash flow |
Significant unobservable input |  |  | Projected revenue and probability of achievement |  |  |  | Projected revenue and probability of achievement |

Deferred Financing Costs

The Company has recorded deferred financing costs as a result of fees incurred by the Company in conjunction with its debt financing activities. These costs are amortized to interest expense using the straight-line method which approximates the interest rate method over the term of the related debt. As of March 31, 2022 and December 31, 2021, unamortized deferred financing costs were $129,791, and $134,528, respectively and are netted against the related debt.

Business Combinations

The Company accounts for its business combinations using the acquisition method of accounting. Under the acquisition method, assets acquired, liabilities assumed, and consideration transferred are recorded at the date of acquisition at their respective fair values. Definite-lived intangible assets are amortized over the expected life of the asset. Any excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill.

Goodwill represents the excess purchase price over the fair value of the tangible net assets and intangible assets acquired in a business combination. Acquisition-related expenses are recognized separately from business combinations and are expensed as incurred. If the business combination provides for contingent consideration such as earn-outs, the Company records the contingent consideration at fair value at the acquisition date. The Company remeasures fair value as of each reporting date and changes resulting from events after the acquisition date, are recognized as follows: 1) if the contingent consideration is classified as equity, the contingent consideration is not re-measured and its subsequent settlement is accounted for within equity, or 2) if the contingent consideration is classified as a liability, the changes in fair value and accretion costs are recognized in earnings.

9

Identifiable Intangible Assets, net

Finite-lived intangible assets such as customer relationships assets, trademarks and tradenames are amortized over their estimated useful lives, generally on a straight-line basis for periods ranging from 3 to 20 years. Finite-lived intangible assets are reviewed for impairment or obsolescence whenever events or circumstances indicate that the carrying amount of the asset may not be recoverable. Recoverability of intangible assets is measured by a comparison of the carrying amount of the asset to the future undiscounted net cash flows expected to be generated by that asset. If the asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the estimated fair value. No impairment was recognized during the periods presented.

Goodwill and other indefinite-lived intangibles

The Company records goodwill when the purchase price of a business acquisition exceeds the estimated fair value of net identified tangible and intangible assets acquired. Goodwill is assigned to a reporting unit on the acquisition date and tested for impairment at least annually, or more frequently when events or changes in circumstances indicate that the fair value of a reporting unit has more likely than not declined below its carrying value. Similarly, indefinite-lived intangible assets (if any) other than goodwill are tested annually or more frequently if indicated, for impairment. If impaired, intangible assets are written down to fair value based on the expected discounted cash flows.

Financial Instruments

The Company evaluates issued financial instruments for classification as either equity or liability based on an assessment of the financial instrument’s specific terms and applicable authoritative guidance in ASC 480, Distinguishing Liabilities from Equity (“ASC 480”) and ASC 815, Derivatives and Hedging (“ASC 815”). The assessment considers whether the financial instruments issued are freestanding pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and, if applicable whether the financial instruments meet all of the requirements for equity classification under ASC 815, including whether the financial instruments are indexed to the Company’s own Common Stock, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of issuance and as of each subsequent reporting period end date while the financial instruments are outstanding. Financial instruments that are determined to be liabilities under ASC 480 or ASC 815 are held at their initial fair value and remeasured to fair value at each subsequent reporting date, with changes in fair value recorded as a non-operating, non-cash loss or gain, as applicable.

The Company’s financial instruments consist of derivatives related to the warrants issued with the securities purchase agreement as discussed in Note 9, Warrant Liabilities. The accounting treatment of derivative financial instruments requires that we record the derivatives at their fair values as of the inception date of the debt agreements and at fair value as of each subsequent balance sheet date. Any change in fair value is recorded as non-operating, non-cash income or expense at each balance sheet date. Upon the determination that an instrument is no longer subject to derivative accounting, the fair value of the derivative instrument at the date of such determination will be reclassified to paid in capital.

Revenue Recognition

The Company recognizes revenue in accordance with Accounting Standards Codification (ASC) 606 Revenue from Contracts with Customers which at its core, recognizes revenue upon the transfer of promised goods or services to customers in an amount that reflects the consideration the entity expects to be entitled to in exchange for those goods or services.

The Company’s revenue is primarily comprised of agency commissions earned from insurance carriers (the “Customer” or “Carrier”) related to insurance plans produced through brokering, producing and servicing agreements between insurance carriers and members. The Company defines a “Member” as an individual, family or entity currently covered or seeking insurance coverage.

The Company focuses primarily on agency services for insurance products in the “Healthcare” and property and casualty, which includes auto (collectively “P&C”) space, with nominal activity in the life insurance and bond sectors. Healthcare includes plans for individuals and families, Medicare supplements, ancillary and small businesses. The Company also earns revenue in the “Insurance Marketing” space as discussed further below.

Consideration for all agency services typically is based on commissions calculated by applying contractual commission rates to policy premiums. For P&C, commission rates are applied to premiums due, whereas for healthcare, commission rates, including override commissions, are applied to monthly premiums received by the Carrier.

The Company has two forms of billing practices, “Direct Bill” and “Agency Bill”. With Direct Bill, Carriers bill and collect policy premium payments directly from Members without any involvement from the Company. Commissions are paid to the Company by the Carrier in the following month. With Agency Bill, the Company bills Members premiums due and remits them to Carriers net of commission earned.

The following outlines the core principles of ASC 606:

Identification of the contract, or contracts, with a customer. A contract with a customer exists when (i) we enter into an enforceable contract with a customer that defines each party’s rights regarding the goods or services to be transferred and identifies the payment terms related to these goods or services, (ii) the contract has commercial substance, and (iii) we determine that collection of substantially all consideration for goods or services that are transferred is probable based on the customer’s intent and ability to pay the promised consideration.

10

Identification of the performance obligations in the contract. Performance obligations promised in a contract are identified based on the goods or services that will be transferred to the customer that are both capable of being distinct, whereby the customer can benefit from the goods or service either on its own or together with other resources that are readily available from third parties or from us, and are distinct in the context of the contract, whereby the transfer of the goods or services is separately identifiable from other promises in the contract.

Determination of the transaction price. The transaction price is determined based on the consideration to which we will be entitled in exchange for transferring goods or services to the customer.

Allocation of the transaction price to the performance obligations in the contract. If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation based on a relative standalone selling price basis.

Recognition of revenue when, or as, the Company satisfies a performance obligation. The Company satisfies performance obligations either over time or at a point in time, as discussed in further detail below. Revenue is recognized at the time the related performance obligation is satisfied by transferring the promised good or service to the customer.

Healthcare revenue recognition:

The Company identifies a contract when it has a binding agreement with a Carrier, the Customer, to provide agency services to Members.

There typically is one performance obligation in contracts with Carriers, to perform agency services that culminate in monthly premium cash collections by the Carrier. The performance obligation is satisfied through a combination of agency services including, marketing carrier’s insurance plans, soliciting Member applications, binding, executing and servicing insurance policies on a continuous basis throughout a policy’s life cycle which includes and culminates with the Customer’s collection of monthly premiums. No commission is earned if cash is not received by Carrier. Thus, commission revenue is earned only after a month’s cash receipts from Members’ dues is received by the Customer. Each month’s Carrier cash collections is considered a separate unit sold and transferred to the Customer i.e., the satisfaction of that month’s performance obligation.

Transaction price is typically stated in a contract and usually based on a commission rate applied to Member premiums paid and received by Carrier. The Company generally continues to receive commission payments from Carriers until a Member’s plan is cancelled or the Company terminates its agency agreement with the Carrier. Upon termination, the Company normally will no longer receive any commissions from Carriers even on business still in place. In some instances, trailing commissions could occur which would be recognized similar to other Healthcare revenue. With one performance obligation, allocation of transaction price is normally not necessary.

Healthcare typically utilizes the Direct Bill method.

The Company recognizes revenue at a point in time, when it satisfies its monthly performance obligation and control of the service transfers to the Customer. Transfer occurs when Member insurance premium cash payments are received by the Customer. The Customer’s receipt of cash is the culmination and complete satisfaction of the Company’s performance obligation, and the earnings process is complete.

With Direct Bill, since the amount of monthly Customer cash receipts is unknown to the Company until the following month when notice is provided by Customer to Company, the Company accrues revenue at each period end. Any estimated revenue accrued and recognized at a period-end is trued up for financial reporting per actual revenue earned as provided by the Customer during the following month.

11

P&C revenue recognition:

The Company identifies a contract when it has a binding agreement with a Carrier, the Customer, to provide agency services to Members.

There typically is one performance obligation in contracts with Customers, to perform agency services to solicit, receive proposals and bind insurance policies culminating with policy placement. Commission revenue is earned at the time of policy placement.

Transaction price is typically stated in a contract and usually based on commission rates applied to Member premiums due. With one performance obligation, allocation of transaction price is normally not necessary.

P&C utilizes both the Agency Bill and Direct Bill methods, depending on the Carrier.

The Company recognizes revenue at a point in time when it satisfies its performance obligation and control of the service transfers to the Customer. Transfer occurs when the policy placement process is complete.

With both Direct Bill and Agency Bill, the Company accrues commission revenue in the period policies are placed. With Agency Bill, payment is typically received from Members in the month earned, however with Direct Bill, payment is typically received from Carriers in the month subsequent to the commissions being earned.

Insurance Marketing revenue recognition:

Medigap, a consolidated wholly owned subsidiary of the Company earns commission revenue by selling bound insurance policies with all renewal rights to insurance marketing organizations (the “IM Customer”). The IM Customers utilize innovative actuarial models to value and price policies purchased based on future projections. IM Customers pay a one-time commission per policy purchased to selling agencies based on a pre-agreed formula outlined in the parties’ contractual agreement. Commission payments are subject to chargeback in the event a policy is cancelled or lapses within 3 months of a policy’s effective date or until the first three payments are received from the insured party, depending on the IM Customer Contract.

The Company identifies a contract when it has a binding agreement to sell issued insurance policies to the IM Customer.

There is one performance obligation in IM Customer contracts, to sell the rights in Company procured issued insurance policies to the IM Customer. The performance obligation is satisfied when the rights to an issued policy have been transferred to the IM Customer.

Transaction price is stated in a contract and is a set range of commission amounts based on each policy sold. There are two variable components to consideration received:

| a) | Commissions are only earned once a policy is “Placed”, defined as, an active policy sold to the IM Customer where the IM Customer has received the initial insurance carrier payment with respect to such policy. The Company requires end-user insured parties to pay the initial premium to the insurance carrier upon issuance of a policy. Insurance carrier in turn pays IM Customer its initial payment soon thereafter. Thus, upon sale of an issued policy to IM Customer, the Company has provided a bound issued policy and ensured first premium payment has been completed by insured party. This results in virtual assurance that the IM Customer will receive its initial insurance carrier payment, and it is more than probable that a significant revenue reversal will not occur. The Company thus considers all policies sold to the IM Customer to be Placed for revenue recognition purposes.
| b) | Commission revenue is subject to chargeback in full if a policy is cancelled or lapses within three months from the policy effective date or if the insured party does not make the first three payments of the policy. The Company uses historical activity as well as current factors to estimate the unconstrained variable consideration for recognition per the expected value method. A chargeback reserve liability is credited for the difference between cash consideration received and variable consideration recognized. At each reporting period, the Company remeasures the chargeback reserve liability and recognizes any change as an increase or decrease to the then current period revenue. As of March 31, 2022 and December 31, 2021, the chargeback reserve liability was $1,585,435 and $0, respectively.

With one performance obligation, allocation of transaction price is normally not necessary.

The Company recognizes revenue at a point in time when it satisfies its performance obligation and control of an insurance policy transfers to the IM Customer. Transfer of control occurs when the Company submits the Policy to the IM Customer.

IM Customers generally pay the Company weekly, and accruals are recorded as necessary at period end.

Other revenue policies: Insurance commissions earned from Carriers for life insurance products are recorded gross of amounts due to agents, with a corresponding commission expense for downstream agent commissions being recorded as commission expense within the condensed consolidated statements of operations.

When applicable, commission revenue is recognized net of any deductions for estimated commission adjustments due to lapses, policy cancellations, and revisions in coverage.

The Company could earn additional revenue from contingent commissions, profit-sharing, override and bonuses based on meeting certain revenue or profit targets established periodically by the Carriers (collectively, “Contingent Commissions”). Contingent Commissions are earned when the Company achieves targets established by Carriers. The Carriers notify the Company when it has achieved the target. The Company recognizes revenue for any Contingent Commissions at the time it is reasonably assured that a significant revenue reversal is not probable, which is generally when a Carrier notifies the Company that it is on track or has earned a Contingent Commission.

The following table disaggregates the Company’s revenue by line of business, showing commissions earned:

SCHEDULE OF DISAGGREGATION REVENUE

Three Months ended March 31, 2022 |  | Medical/Life |  |  | Property and Casualty |  |  | Total |
Regular |  |  |  |  |  |  |  |  |  |  |  |
EBS |  | $ | 221,184 |  |  | $ | - |  |  | $ | 221,184 |
USBA |  |  | 13,587 |  |  |  | - |  |  |  | 13,587 |
CCS/UIS |  |  | - |  |  |  | 43,881 |  |  |  | 43,881 |
Montana |  |  | 506,721 |  |  |  | - |  |  |  | 506,721 |
Fortman |  |  | 332,600 |  |  |  | 197,260 |  |  |  | 529,860 |
Altruis |  |  | 1,304,872 |  |  |  | - |  |  |  | 1,304,872 |
Kush |  |  | 438,591 |  |  |  | - |  |  |  | 438,591 |
Medigap |  |  | 1,177,085 |  |  |  | - |  |  |  | 1,177,085 |
|  | $ | 3,994,640 |  |  | $ | 241,141 |  |  | $ | 4,235,781 |

Three Months ended March 31, 2021 |  | Medical/Life |  |  | Property and Casualty |  |  | Contingent commission |  |  | Total |
Regular |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
EBS |  |  | 208,994 |  |  |  | - |  |  |  | - |  |  |  | 208,994 |
USBA |  |  | 12,225 |  |  |  | - |  |  |  | - |  |  |  | 12,225 |
CCS/UIS |  |  | - |  |  |  | 88,818 |  |  |  | - |  |  |  | 88,818 |
Montana |  |  | 535,116 |  |  |  | - |  |  |  | - |  |  |  | 535,116 |
Fortman |  |  | 249,801 |  |  |  | 207,772 |  |  |  | - |  |  |  | 457,573 |
Altruis |  |  | 1,021,004 |  |  |  | - |  |  |  | - |  |  |  | 1,021,004 |
|  |  | 2,027,140 |  |  |  | 296,590 |  |  |  | - |  |  |  | 2,323,730 |

12

General and Administrative

General and administrative expenses primarily consist of personnel costs for the Company’s administrative functions, professional service fees, office rent, all employee travel expenses, and other general costs.

Marketing and Advertising

The Company’s direct channel expenses primarily consist of costs for e-mail marketing and newspaper advertisements. The Company’s online advertising channel expense primarily consist of social media ads. Advertising costs for both direct and online channels are expensed as incurred.

Stock-Based Compensation

Stock-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as an expense on a straight-line basis over the requisite service period, based on the terms of the awards. The fair value of the stock-based payments to nonemployees that are fully vested and non-forfeitable as at the grant date is measured and recognized at that date unless there is a contractual term for services in which case such compensation would be amortized over the contractual term. As the Reliance Global Group, Inc. Equity Incentive Plan 2019 was adopted in January of 2019, the Company lacks the historical basis to estimate forfeitures and will recognize forfeitures as they occur.

Leases

The Company recognizes leases in accordance with Accounting Standards Codification Topic 842, “Leases” (“ASC 842” or “ASU 2016-12”). This standard provides enhanced transparency and comparability by requiring lessees to record right-of-use assets and corresponding lease liabilities on the balance sheet for most leases. Expenses associated with leases are recognized as a single lease expense, generally on a straight-line basis.

The Company is the lessee in a contract when the Company obtains the right to use an asset. We currently lease real estate and office space under non-cancelable operating lease agreements. When applicable, consideration in a contract is allocated between lease and non-lease components. Lease payments are discounted using the implicit discount rate in the lease. If the implicit discount rate for the lease cannot be readily determined, the Company uses an estimate of its incremental borrowing rate. The Company did not have any contracts accounted for as finance leases as of March 31, 2021, or 2020. Operating leases are included in the line items right-of-use assets, current portion of leases payable, and leases payable, less current portion in the condensed consolidated balance sheets. Right-of-use (“ROU”) asset represents the Company’s right to use an underlying asset for the lease term and lease obligations represent the Company’s obligations to make lease payments arising from the lease, both of which are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. Leases with a lease term of 12 months or less at inception are not recorded on the condensed consolidated balance sheet and are expensed on a straight-line basis over the lease term in the condensed consolidated statement of operations. The Company determines a lease’s term by agreement with lessor and includes lease extension options and variable lease payments when option and/or variable payments are reasonably certain of being exercised or paid.

Income Taxes

The Company recognizes deferred tax assets and liabilities using enacted tax rates for the effect of temporary differences between the book and tax basis of recorded assets and liabilities. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that some portion or all of the deferred tax asset will not be realized. In evaluating its ability to recover deferred tax assets within the jurisdiction in which they arise, the Company considers all available positive and negative evidence, including the expected reversals of taxable temporary differences, projected future taxable income, taxable income available via carryback to prior years, tax planning strategies, and results of recent operations. The Company assesses the realizability of its deferred tax assets, including scheduling the reversal of its deferred tax assets and liabilities, to determine the amount of valuation allowance needed. Scheduling the reversal of deferred tax asset and liability balances requires judgment and estimation. The Company believes the deferred tax liabilities relied upon as future taxable income in its assessment will reverse in the same period and jurisdiction and are of the same character as the temporary differences giving rise to the deferred tax assets that will be realized.

13

Seasonality

A greater number of the Company’s Medicare-related health insurance plans are sold in the fourth quarter during the Medicare annual enrollment period when Medicare-eligible individuals are permitted to change their Medicare Advantage. The majority of the Company’s individual and family health insurance plans are sold in the annual open enrollment period as defined under the federal Patient Protection and Affordable Care Act and related amendments in the Health Care and Education Reconciliation Act. Individuals and families generally are not able to purchase individual and family health insurance outside of these open enrollment periods, unless they qualify for a special enrollment period as a result of certain qualifying events, such as losing employer-sponsored health insurance or moving to another state.

Prior Period Adjustments

During the June 30, 2021 quarterly financial reporting close process, the Company identified certain immaterial adjustments impacting the prior reporting period. Specifically, the Company identified adjustments to correct asset, liability and equity accounts in relation to historical purchase price allocation accounting, adjustments to true up accounts receivable and retained earnings for certain historical accrued revenues and true up the common stock issuable account.

The Company has also separately reclassified its purchase software from property, plant and equipment to intangible assets which had no impact on the condensed consolidated statement of operations.

The Company assessed the materiality of the adjustments to prior period financial statements in accordance with Securities and Exchange Commission Staff Accounting Bulletin No. (SAB) 99, Materiality, and SAB 108, Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements, and ASC 250, Accounting Changes and Error Corrections.

Accordingly, the Company’s comparative condensed consolidated financial statements and impacted notes have been revised from amounts previously reported to reflect these adjustments. The following table illustrates the impact on previously reported amounts and adjusted balances presented in the condensed consolidated financial statements for the period ended March 31, 2022.

SUMMARIZES THE CHANGES TO THE PREVIOUSLY ISSUED FINANCIAL INFORMATION

Account |  | 3/31/2021 As reported |  |  | Adjustment |  |  | 3/31/2021 Adjusted |
Earn-out liability-Closing balance as of December 31, 2020 |  |  | 2,631,418 |  |  |  | 300,000 |  |  |  | 2,931,418 |
Goodwill-Closing balance as of December 31, 2020 |  |  | 9,265,070 |  |  |  | (503,345 | ) |  |  | 8,761,725 |
Common stock issuable-Closing balance as of December 31, 2020 |  |  | 822,116 |  |  |  | (482,116 | ) |  |  | 340,000 |
Additional paid-in-capital-Closing balance as of December 31, 2020 |  |  | 11,377,123 |  |  |  | 182,116 |  |  |  | 11,559,239 |
Accumulated Deficit-Closing balance as of December 31, 2020 |  |  | (12,482,281 | ) |  |  | 122,601 |  |  |  | (12,359,680 | )
Common stock issuable |  |  | 482,116 |  |  |  | (482,116 | ) |  |  | - |
Accumulated Deficit |  |  | (13,123,609 | ) |  |  | 150,003 |  |  |  | (12,973,606 | )
Additional paid-in-capital |  |  | 25,810,147 |  |  |  | 182,116 |  |  |  | 25,992,263 |
Commission income |  |  | 2,296,328 |  |  |  | 27,402 |  |  |  | 2,323,730 |
Total Revenue |  |  | 2,296,328 |  |  |  | 27,402 |  |  |  | 2,323,730 |
Net Loss |  |  | (641,328 | ) |  |  | 27,402 |  |  |  | (613,926 | )
EPS |  |  | (0.09 | ) |  |  | (0.01 | ) |  |  | (0.08 | )

Recently Issued Accounting Pronouncements

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses (“ASU 2016-13”), which requires the measurement of expected credit losses for financial instruments carried at amortized cost, such as accounts receivable, held at the reporting date based on historical experience, current conditions and reasonable forecasts. The main objective of this ASU is to provide financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. In November 2018, the FASB issued ASU No. 2018-19, Codification Improvements to Topic 326, Financing Instruments—Credit Losses. ASU 2016-13 is effective for fiscal years beginning after December 15, 2019. On November 15, 2019, the FASB delayed the effective date of FASB ASC Topic 326 for certain small public companies and other private companies. As amended, the effective date of ASC Topic 326 was delayed until fiscal years beginning after December 15, 2022 for SEC filers that are eligible to be smaller reporting companies under the SEC’s definition. The Company does not currently believe the adoption of this standard will have a significant impact on its financial statements, given its history of minimal bad debt expense relating to trade accounts receivable.

In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which eliminates certain exceptions to the general principles in Topic 740 and simplifies other areas of the existing guidance. ASU 2019-12 is effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. Early adoption is permitted. The Company adopted this pronouncement January 1, 2021 which did not have a material effect on the condensed consolidated financial statements.

In August 2020, the FASB issued Accounting Standards Update (“ASU”) No. 2020-06, Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU also removes certain settlement conditions that are required for equity-linked contracts to qualify for the derivative scope exception, and it simplifies the diluted earnings per share calculation in certain areas. The ASU is effective for fiscal years beginning after December 15, 2021. The Company adopted ASU 2020-06 on January 1, 2022, which did not have a material impact on the condensed consolidated financial statements.

In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers, which amends ASC 805 to require an acquirer to, at the date of acquisition, recognize and measure contract assets and contract liabilities acquired in accordance with ASU 2014-9, Revenue from Contracts with Customers (Topic 606) as if the entity had originated the contracts. The guidance is effective for fiscal years beginning after December 15, 2022 with early adoption permitted. The Company elected to early adopt ASU 2021-08 as of January 1, 2022, which did not have a material impact on the condensed consolidated financial statements.

14

NOTE 3. STRATEGIC INVESTMENTS AND BUSINESS COMBINATIONS

As of March 31, 2022, we have acquired nine insurance brokerages (see table below), including both acquisitions of affiliated companies (i.e., owned by Reliance Holdings before the acquisition) and unaffiliated companies. As our acquisition strategy continues, our reach within the insurance arena can provide us with the ability to offer lower rates, which could boost our competitive position within the industry.

Acquired |  | Date |  | Location |  | Line of Business |  | Status
U.S. Benefits Alliance, LLC (USBA) |  | October 24, 2018 |  | Michigan |  | Health Insurance |  | Affiliated
Employee Benefit Solutions, LLC (EBS) |  | October 24, 2018 |  | Michigan |  | Health Insurance |  | Affiliated
Commercial Solutions of Insurance Agency, LLC (CCS or Commercial Solutions) |  | December 1, 2018 |  | New Jersey |  | P&C – Trucking Industry |  | Unaffiliated
Southwestern Montana Insurance Center, Inc. (Southwestern Montana or Montana) |  | April 1, 2019 |  | Montana |  | Group Health Insurance |  | Unaffiliated
Fortman Insurance Agency, LLC (Fortman or Fortman Insurance) |  | May 1, 2019 |  | Ohio |  | P&C and Health Insurance |  | Unaffiliated
Altruis Benefits Consultants, Inc. (Altruis) |  | September 1, 2019 |  | Michigan |  | Health Insurance |  | Unaffiliated
UIS Agency, LLC (UIS) |  | August 17, 2020 |  | New York |  | Health Insurance |  | Unaffiliated
J.P. Kush and Associates, Inc. (Kush) |  | May 1, 2021 |  | Michigan |  | Health Insurance |  | Unaffiliated
Medigap Healthcare Insurance Company, LLC (Medigap) |  | January 10, 2022 |  | Florida |  | Health Insurance |  | Unaffiliated

15

J.P. Kush and Associates, Inc. Transaction

On May 1, 2021, the Company entered into a Purchase Agreement with J.P. Kush and Associates, Inc. whereby the Company shall purchase the business and certain assets noted within the Purchase Agreement (the “Kush Acquisition”) for a total purchase price of $3,644,166. The purchase price was paid with a cash payment of $1,900,000, $50,000 in restricted shares of the Company’s common stock, in a transaction exempt from registration under Section 4(a)(2) of the Securities Act of 1933, as amended, and an earn-out payment.

The Kush Acquisition was accounted for as a business combination in accordance with the acquisition method under the guidance in ASC 805-10 and 805-20. Accordingly, the total purchase consideration was allocated to intangible assets acquired based on their respective estimated fair values. The acquisition method of accounting requires, among other things, that assets acquired, and liabilities assumed, if any, in a business purchase combination be recognized at their fair values as of the acquisition date. The process for estimating the fair values of identifiable intangible assets and certain tangible assets requires the use of significant estimates and assumptions, including estimating future cash flows, developing appropriate discount rates, estimating the costs, and timing.

The allocation of the purchase price in connection with the Kush Acquisition was calculated as follows:

SCHEDULE OF ALLOCATION OF PURCHASE PRICE

Description |  | Fair Value |  |  | Weighted Average Useful Life (Years)
Accounts receivable |  | $ | 291,414 |  |  |
Trade name and trademarks |  |  | 685,400 |  |  | 5
Customer relationships |  |  | 551,000 |  |  | 10
Non-competition agreements |  |  | 827,800 |  |  | 5
Goodwill |  |  | 1,288,552 |  |  | Indefinite
Purchase consideration allocated |  | $ | 3,644,166 |  |  |

Goodwill of $1,288,552 arising from the Kush Acquisition consisted of the value of the employee workforce and the residual value after all identifiable intangible assets were valued. Goodwill recognized pursuant to the Kush Acquisition is currently expected to be deductible for income tax purposes. Total acquisition costs for the Kush Acquisition incurred were $58,092 recorded as a component of General and administrative expenses. The approximate revenue and net profit for the acquired business as a standalone entity per ASC 805 from January 1, 2021 to April 30, 2021 was $500,000 and $219,097, respectively.

Pro Forma Information

The results of operations of J.P. Kush and Associates, Inc. will be included in the Company’s consolidated financial statements as of the date of acquisition through the current period end. The following supplemental approximate pro forma combined financial information assumes that the acquisition had occurred at the beginning of the three months ended March 31, 2021:

SCHEDULE OF PRO FORMA INFORMATION RELATED TO ACQUISITION

|  |  | March 31, |
|  | 2021 |
Revenue |  | $ | 2,695,843 |
Net Income (Loss) |  | $ | (450,868 | )
Earnings (Loss) per common share, basic |  | $ | (0.90 | )
Earnings (Loss) per common share, diluted |  | $ | (0.90 | )

Medigap Healthcare Insurance Company, LLC Transaction

On January 10, 2022, the Company completed the acquisition of all assets of Medigap Healthcare Insurance Company, LLC (“Medigap”) pursuant to which the Company purchased all of the assets of Medigap for a purchase price in the amount of $20,096,250 consisting of payment to Medigap of (i) $18,138,750 in cash and (ii) issuing to seller 40,402 shares of the Company’s restricted common stock in a transaction exempt from registration under Section 4(a)(2) of the Securities Act of 1933, as amended. The purchase price is subject to post-closing adjustment to reconcile certain pre-closing credits and liabilities of the parties. The shares issued to Medigap as part of the purchase price are subject to lock up arrangements pursuant to which 50% of those shares may be sold after the one-year anniversary of the date of Closing the APA and the balance of the shares after the second-year anniversary of the date of closing under the APA.

16

The acquisition of Medigap was accounted for as a business combination in accordance with the acquisition method pursuant to FASB Topic No. 805, Business Combination (ASC 805). Accordingly, the total purchase consideration was allocated to the assets acquired, and liabilities assumed based on their respective estimated fair values. The acquisition method of accounting requires, among other things, that assets acquired, and liabilities assumed, if any, in a business purchase combination be recognized at their fair values as of the acquisition date. The process for estimating the fair values of identifiable intangible assets and certain tangible assets requires the use of significant estimates and assumptions, including estimating future cash flows, developing appropriate discount rates, estimating the costs, and timing.

The preliminary allocation of the purchase price in connection with the acquisition of Medigap was calculated as follows:

SCHEDULE OF ALLOCATION OF PURCHASE PRICE

Description |  | Fair Value |  |  | Weighted Average Useful Life (Years)
Property, plant and equipment |  | $ | 20,666 |  |  | 5
Right-of-use asset |  |  | 317,787 |  |  |
Trade names |  |  | 340,000 |  |  | 15
Customer relationships |  |  | 4,550,000 |  |  | 12
Technology |  |  | 67,000 |  |  | 3
Backlog |  |  | 210,000 |  |  | 1
Chargeback reserve |  |  | (1,484,473 | ) |  |
Lease liability |  |  | (317,787 | ) |  |
Goodwill |  |  | 19,199,008 |  |  | Indefinite
|  | $ | 22,902,201 |  |  |

Trade name was measured at fair value using the relief-from-royalty method under the income approach. Significant inputs used to measure the fair value include an estimate of projected revenue from the trade name, a pre-tax royalty rate of 0.5% and a discount rate of 11.0%.

Customer relationships were measured at fair value using the multiple-period excess earnings method under the income approach. Significant inputs used to measure the fair value include an estimate of projected revenue and costs associated with existing customers, and a discount rate of 11.0%.

Technology was measured at fair value using the cost replacement method of the cost approach. Significant inputs used to measure the fair value include an estimate of cost to replace, an obsolescence rate of 40.3%.

The value assigned to backlog acquired was estimated based upon the contractual nature of the backlog as of the acquisition date, using the income approach to discount back to present value the cash flows attributable to the backlog, using a discount rate of 11.0%.

Goodwill of $19,199,008 arising from the acquisition of Medigap consisted of the value of the employee workforce and the residual value after all identifiable intangible assets were valued. Goodwill recognized pursuant to the acquisition of Medigap is currently expected to be deductible for income tax purposes. Total acquisition costs for the acquisition of Medigap incurred were $94,065 recorded as a component of General and administrative expenses.

The approximate revenue and net profit or loss for the acquired business as a standalone entity per ASC 805 from January 10, 2022 to March 31, 2022 was $1,177,000 and a loss of $148,000, respectively.

Pro Forma Information

The results of operations of Medigap will be included in the Company’s consolidated financial statements as of the date of acquisition through the current period end. The following supplemental pro forma approximate combined financial information assumes that the acquisition had occurred at the beginning of the three months ended March 31, 2022 and 2021:

SCHEDULE OF PRO FORMA INFORMATION RELATED TO ACQUISITION

|  |  | March 31, |  |  |  | March 31, |
|  | 2022 |  |  | 2021 |
Revenue |  | $ | 4,659,451 |  |  | $ | 3,602,106 |
Net Income (Loss) |  | $ | 9,355,584 |  |  | $ | (566,903 | )
Earnings (Loss) per common share, basic |  | $ | 7.65 |  |  | $ | 1.2 | )
Earnings (Loss) per common share, diluted |  | $ | 1.80 |  |  | $ | 1.2 | )

NOTE 4. INVESTMENT IN NSURE, INC.

On February 19, 2020, the Company entered into a securities purchase agreement with NSURE, Inc. (“NSURE”) whereas the Company may invest up to an aggregate of $20,000,000 in NSURE which will be funded with three tranches. In exchange, the Company will receive a total of 5,837,462 shares of NSURE’s Class A Common Stock, which represents 35% of the outstanding shares. The first tranche of $1,000,000 was paid immediately upon execution of the agreement. As a result of the first tranche, the Company received 291,873 shares of NSURE’s Class A Common Stock. The second tranche of $3,000,000 and third tranche of $16,000,000 have not occurred as of March 31, 2022. The Company will use the cost method of acquisition for the initial recognition method of this investment. Once the Company determines that it can exercise significant influence over NSURE, it will begin to account for its investment under the equity method. On June 1, 2020, the Company invested an additional $200,000 and received 58,375 shares of NSURE Class A Common Stock. On August 5, 2020 and August 20, 2020, the Company invested an additional $100,000 and $50,000, respectively, for which the Company received 43,781 shares of NSURE Class A common stock. As of March 31, 2022, the investment balance is $1,350,000.

On February 10, 2020, the Company issued 3,111 shares of common stock to a third-party individual for the purpose of raising capital to fund the Company’s investment in NSURE, Inc. The Company received proceeds of $1,000,000 for the issuance of these common shares.

17

NOTE 5. PROPERTY AND EQUIPMENT

Property and equipment consists of the following:

SCHEDULE OF PROPERTY AND EQUIPMENTS

|  | March 31, 2022 |  |  | December 31, 2021 |
Computer equipment |  | $ | 79,379 |  |  | $ | 72,110 |
Office equipment and furniture |  |  | 48,616 |  |  |  | 36,157 |
Leasehold Improvements |  |  | 94,486 |  |  |  | 89,819 |
Property and equipment |  |  | 222,481 |  |  |  | 198,086 |
Less: Accumulated depreciation |  |  | (75,341 | ) |  |  | (67,727 | )
Property and equipment, net |  | $ | 147,140 |  |  | $ | 130,359 |

Depreciation expense associated with property and equipment, as adjusted to reclassify certain software assets to intangibles, is included within depreciation and amortization in the Company’s condensed consolidated statements of operations and is, $7,614 and $2,658 for the three months ended March 31, 2022 and 2021, respectively.

NOTE 6. GOODWILL AND OTHER INTANGIBLE ASSETS

Effective January 1, 2020 the Company reorganized its reporting structure into a single operating unit. All of the acquisitions made by the Company are in one industry insurance agencies. These agencies operate in a very similar economic and regulatory environment. The Company has one executive who is responsible for the operations of the insurance agencies. This executive reports directly to the Chief Financial Officer (“CFO”) on a quarterly basis. Additionally, the CFO who is responsible for the strategic direction of the Company reviews the operations of the collective insurance agency business as opposed to an office-by-office view. In accordance with guidance in ASC 350-20-35-45, all the Company’s goodwill will be reassigned to a single reporting unit.

For the year ended December 31, 2021 the Company assessed goodwill in accordance with ASC 350-20-35-3, analyzing the relevant qualitative factors. The Company noted that it was not more likely than not that the fair value of the reporting unit is less than its carrying amount, thus determining that the two-step goodwill impairment test was not required. Pursuant to the qualitative assessment, the Company concluded that goodwill was not impaired and this conclusion remains reasonable as of March 31, 2022.

The following table rolls forward the Company’s goodwill balance for the periods ending March 31, 2022 and December 31, 2021. As discussed in Note 2 - Prior Period Adjustments, a $(503,345) adjustment was identified for goodwill which impacted the closing December 31, 2020 balance in the same amount. Accordingly, the December 31, 2020 balance is adjusted in the following table from the originally reported balance of $9,265,070 to $8,761,725.

SCHEDULE OF IMPAIRMENT OF GOODWILL

|  | Goodwill |
December 31, 2020 |  | $ | 8,761,725 |
Goodwill recognized in connection with Kush acquisition on May 1, 2021 |  | $ | 1,288,552 |
December 31, 2021 |  | $ | 10,050,277 |
Goodwill recognized in connection with Medigap acquisition on January 10, 2022 |  | $ | 19,199,008 |
March 31, 2022 |  | $ | 29,249,285 |

18

The following table sets forth the major categories of the Company’s intangible assets and the weighted-average remaining amortization period as of March 31, 2022:

SCHEDULE OF INTANGIBLE ASSETS AND WEIGHTED-AVERAGE REMAINING AMORTIZATION PERIOD

|  | Weighted Average Remaining Amortization period (Years) |  |  | Gross Carrying Amount |  |  | Accumulated Amortization |  |  | Net Carrying Amount |
Trade name and trademarks |  |  | 5.1 |  |  | $ | 2,117,475 |  |  | $ | (701,666 | ) |  | $ | 1,415,809 |
Internally developed software |  |  | 4.4 |  |  |  | 881,586 |  |  |  | (67,682 | ) |  |  | 813,904 |
Customer relationships |  |  | 9.7 |  |  |  | 8,787,290 |  |  |  | (1,239,562 | ) |  |  | 7,547,728 |
Purchased software |  |  | 0.3 |  |  |  | 562,327 |  |  |  | (499,846 | ) |  |  | 62,481 |
Video Production Assets |  |  | 0.8 |  |  |  | 50,000 |  |  |  | (9,863 | ) |  |  | 40,137 |
Non-competition agreements |  |  | 2.6 |  |  |  | 3,504,809 |  |  |  | (1,653,617 | ) |  |  | 1,851,192 |
Contracts Backlog |  |  | 0.8 |  |  |  | 210,000 |  |  |  | (46,028 | ) |  |  | 163,972 |
|  |  |  |  |  | $ | 16,113,487 |  |  | $ | (4,218,264 | ) |  | $ | 11,895,223 |

The following table sets forth the major categories of the Company’s intangible assets and the weighted-average remaining amortization period as of December 31, 2021:

|  | Weighted Average Remaining Amortization period (Years) |  |  | Gross Carrying Amount |  |  | Accumulated Amortization |  |  | Net Carrying Amount |
Trade name and trademarks |  |  | 3.5 |  |  | $ | 1,777,475 |  |  | $ | (609,822 | ) |  | $ | 1,167,653 |
Internally developed software |  |  | 4.7 |  |  |  | 595,351 |  |  |  | (28,443 | ) |  |  | 566,908 |
Customer relationships |  |  | 7.7 |  |  |  | 4,237,290 |  |  |  | (1,048,726 | ) |  |  | 3,188,564 |
Purchased software |  |  | 0.6 |  |  |  | 562,327 |  |  |  | (452,985 | ) |  |  | 109,342 |
Video Production Assets |  |  | 1.0 |  |  |  | 20,000 |  |  |  | - |  |  |  | 20,000 |
Non-competition agreements |  |  | 2.9 |  |  |  | 3,504,809 |  |  |  | (1,478,376 | ) |  |  | 2,026,433 |
|  |  |  |  |  | $ | 10,697,252 |  |  | $ | (3,618,352 | ) |  | $ | 7,078,900 |

Amortization expense, as adjusted for certain software reclassifications is, $599,911 and $283,569 for the three months ended March 31, 2022 and 2021, respectively.

The following table reflects expected amortization expense as of March 31, 2022, for each of the following five years and thereafter:

SCHEDULE OF AMORTIZATION EXPENSE OF ACQUIRED INTANGIBLES ASSETS

Years ending December 31, |  | Amortization Expense |
2022 (remainder of year) |  | $ | 1,823,253 |
2023 |  |  | 2,064,243 |
2024 |  |  | 1,771,983 |
2025 |  |  | 1,325,184 |
2026 |  |  | 1,064,552 |
Thereafter |  |  | 3,846,008 |
Total |  | $ | 11,895,223 |

19

NOTE 7. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

Significant components of accounts payable and accrued liabilities were as follows:

SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

|  | March 31, 2022 |  |  | December 31, 2021 |
Accounts payable, |  | $ | 824,129 |  |  | $ | 547,117 |
Accrued expenses |  |  | 116,619 |  |  |  | 2,170,215 |
Accrued credit card payables |  |  | 75,459 |  |  |  | 36,103 |
Other accrued liabilities |  |  | 26,910 |  |  |  | 5,725 |
Accounts payable and accrued liabilities |  | $ | 1,043,117 |  |  | $ | 2,759,160 |

NOTE 8. LONG-TERM DEBT

The composition of the long-term debt follows:

SCHEDULE OF LONG TERM DEBT

|  | March 31, 2022 |  |  | December 31, 2021 |
Oak Street Funding LLC Term Loan for the acquisition of EBS and USBA, net of deferred financing costs of $14,051 and $14,606 as of March 31, 2022 and December 31, 2021, respectively |  | $ | 470,249 |  |  | $ | 485,317 |
Oak Street Funding LLC Senior Secured Amortizing Credit Facility for the acquisition of CCS, net of deferred financing costs of $16,988 and $17,626 as of March 31, 2022 and December 31, 2021, respectively |  |  | 762,051 |  |  |  | 785,826 |
Oak Street Funding LLC Term Loan for the acquisition of SWMT, net of deferred financing costs of $10,556 and $11,027 as of March 31, 2022 and December 31, 2021, respectively |  |  | 859,892 |  |  |  | 884,720 |
Oak Street Funding LLC Term Loan for the acquisition of FIS, net of deferred financing costs of $41,206 and $42,660 as of March 31, 2022 and December 31, 2021, respectively |  |  | 2,164,855 |  |  |  | 2,226,628 |
Oak Street Funding LLC Term Loan for the acquisition of ABC, net of deferred financing costs of $46,989 and $48,609 as of March 31, 2022 and December 31, 2021, respectively |  |  | 3,521,493 |  |  |  | 3,616,754 |
|  |  | 7,778,540 |  |  |  | 7,999,245 |
Less: current portion |  |  | (918,073 | ) |  |  | (913,920 | )
Long-term debt |  | $ | 6,860,467 |  |  | $ | 7,085,325 |

Oak Street Funding LLC – Term Loans and Credit Facilities

During the year ended December 31, 2018 the Company entered into two debt agreements with Oak Street Funding LLC. On August 1, 2018, EBS and USBA entered into a Credit Agreement with Oak Street Funding LLC (“Oak Street”) whereby EBS and USBA borrowed $750,000 from Oak Street under a Term Loan. The Term Loan is secured by certain assets of the Company. Interest accrues at 5.00% on the basis of a 360-day year, maturing 120 months from the Amortization Date (September 25, 2018). The Company incurred debt issuance costs associated with the Term Loan in the amount of $22,188. On December 7, 2018, CCS entered into a Facility with Oak Street whereby CCS borrowed $1,025,000 from Oak Street under a senior secured amortizing credit facility. The borrowing rate under the Facility is a variable rate equal to Prime +1.50% and matures 10 years from the closing date. The Company incurred debt issuance costs associated with the Facility in the amount of $25,506, which were deferred and are amortized over the length of the Facility.

During the year ended December 31, 2019 the Company entered in Credit Agreements with Oak Street on April 1, 2019, May 1, 2019 and September 5, 2019 whereby the Company borrowed a total amount of $7,912,000 from Oak Street under the Term Loans. The Term Loans are secured by certain assets of the Company. The borrowing rates under the Facility is a variable rate equal to Prime + 2.00% and matures 10 years from the closing date. The Company recorded debt issuance costs associated with the aforementioned loans in total of $181,125. Aggregated cumulative maturities of long-term obligations (including the Term Loan and the Facility), excluding deferred financing costs, as of March 31, 2022 are:

20

SCHEDULE OF CUMULATIVE MATURITIES OF LONG-TERM OBLIGATIONS

Fiscal year ending December 31, |  | Maturities of Long-Term Debt |
2022 (remainder of year) |  | $ | 682,348 |
2023 |  |  | 957,233 |
2024 |  |  | 1,010,835 |
2025 |  |  | 1,069,437 |
2026 |  |  | 1,130,416 |
Thereafter |  |  | 3,058,062 |
Total |  |  | 7,908,331 |
Less debt issuance costs |  |  | (129,791 | )
Total |  | $ | 7,778,540 |

NOTE 9. Warrant Liabilities

Series B Warrants

On December 22, 2021 the Company entered into a securities purchase agreement with several institutional buyers for the purchase and sale of (i) warrants to purchase an aggregate of up to 651,997 shares of the Company’s common stock, par value $0.086 per share at an exercise price of $61.35 per share, (ii) an aggregate of 178,060 shares of Common Stock, and (iii) 9,076 shares of the Company’s newly-designated Series B convertible preferred stock, par value $0.086 per share, with a stated value of $1,000 per share, initially convertible into an aggregate of 147,939 shares of Common Stock at a conversion price of $61.35 per share, each a freestanding financial instrument, (the “Private Placement”). The aggregate purchase price for the Common Shares, the Preferred Shares and the Warrants is approximately $20,000,000.

By entering into the Private Placement on December 22, 2021, the Company entered into a commitment to issue the Common Shares, Preferred Shares and Series B Warrants on the Initial Closing Date for a fixed price and exercise price, as applicable. The commitment to issue Series B Warrants (the “Warrant Commitment”) represents a derivative financial instrument, other than an outstanding share, that, at inception, has both of the following characteristics: (i) embodies a conditional obligation indexed to the Company’s equity. The Company classified the commitment to issue the warrants as a derivative liability because it represents a written option that does not qualify for equity accounting The Company initially measured the derivative liability at its fair value and will subsequently remeasure the derivative liability, at fair value with changes in fair value recognized in earnings. An option pricing model was utilized to calculate the fair value of the Warrant Commitment. The Company initially recorded $17,652,808 of non-operating unrealized losses within the recognition and change in fair value of warrant liabilities account for the year ended December 31,2021. The Private Placement closed on January 4, 2022, at which time the Company remeasured the derivative liability for the warrants issued in the transaction. The Company recognized $14,572,126 of non-operating unrealized gains within the recognition and change in fair value of warrant liabilities account on the condensed consolidated statement of operations for the three months ended March 31, 2022, related to the subsequent changes in its fair value through March 31, 2022. A corresponding derivative liability of $23,080,682 is included on Company’s condensed consolidated balance sheet as of March 31, 2022. The closing of the Private Placement settled the subscription receivable reported on the Company’s balance sheet as of December 31, 2021.

Placement Agent Warrants

In connection with the Private Placement, the Company issued 16,303 warrants to the placement agent for the Private Placement. The warrants were issued as compensation for the placement agent’s services. The Placement Agent Warrants are: (i) exercisable on any day after the six (6) month anniversary of the issue date, (ii) expire five years after the closing of the Private Placement, and (iii) exercisable at $61.35 per share. The Placement Agent Warrants contain terms that may require the Company to transfer assets to settle the warrants. Therefore, the Placement Agent Warrants are classified as a derivative liability measured at fair value of $1,525,923 on the date of issuance and will be remeasured each accounting period with the changes in fair value reported in earnings. The Placement Agent Warrants are considered financing expense fees paid to the Placement Agent. Since the financing expenses relate to a derivative liability measured at fair value, this financing expense of $1,525,923, along with non-operating unrealized gains of $946,461, were included in the recognition and change in fair value of warrant liabilities account on the condensed consolidated statement of operations for the three months ended March 31, 2022, A corresponding derivative liability of $579,463 is included on Company’s condensed consolidated balance sheet as of March 31, 2022.

NOTE 10. SIGNIFICANT CUSTOMERS

Customers and IM Customers representing 10% or more of total revenue are presented in the table below:

SCHEDULE OF CONCENTRATIONS OF REVENUES

|  | For the three months ended March 31, |
Insurance Carrier |  | 2022 |  |  | 2021 |
BlueCross BlueShield |  |  | 10 | % |  |  | 22 | %
Priority Health |  |  | 30 | % |  |  | 35 | %
LTC Global |  |  | 25 | % |  |  | - | %

No other single Customer or IM Customer accounted for more than 10% of the Company’s commission revenues. The loss of any significant customer, including Priority Health, BlueCross BlueShield and LTC Global could have a material adverse effect on the Company.

NOTE 11. EQUITY

Preferred Stock

The Company has been authorized to issue 750,000,000 shares of $0.086 par value Preferred Stock. The Board of Directors is expressly vested with the authority to divide any or all of the Preferred Stock into series and to fix and determine the relative rights and preferences of the shares of each series so established, within certain guidelines established in the Articles of Incorporation.

21

Each share of Series A Convertible Preferred Stock shall have ten (10) votes per share and may be converted into ten (10) shares of $0.086 par value common stock. The holders of the Series A Convertible Preferred Stock shall be entitled to receive, when, if and as declared by the Board, out of funds legally available therefore, cumulative dividends payable in cash. The annual interest rate at which cumulative preferred dividends will accrue on each share of Series A Convertible Preferred Stock is 0%. In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, before any distribution of assets of the Corporation shall be made to or set apart for the holders of the Common Stock and subject and subordinate to the rights of secured creditors of the Company, the holders of Series A Preferred Stock shall receive an amount per share equal to the greater of (i) one dollar ($1.00), adjusted for any recapitalization, stock combinations, stock dividends (whether paid or unpaid), stock options and the like with respect to such shares, plus any accumulated but unpaid dividends (whether or not earned or declared) on the Series A Convertible Preferred Stock, and (ii) the amount such holder would have received if such holder has converted its shares of Series A Convertible Preferred Stock to common stock, subject to but immediately prior to such liquidation.

The Series B Convertible Preferred Stock shall have no voting rights and may be converted into 16 shares of $0.086 par value common stock. The holders of the Series B Convertible Preferred Stock are not entitled to receive dividends payable, except that holder of Series B Preferred would be entitled to receive dividends paid on account of the common stock. In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, the Holders shall be entitled to receive out of the assets, whether capital or surplus, of the Corporation the same amount that a holder of Common Stock would receive if the Preferred Stock were fully converted (disregarding for such purposes any conversion limitations hereunder) to Common Stock which amounts shall be paid pari passu with all holders of Common Stock..

In January 2022, the Company issued 9,076 shares of its newly designated Series B convertible preferred stock through the Private Placement for the purpose of raising capital. See Note 9 - Warrant Liabilities for proceeds received by the Company.

As of March 31, 2022 and December 31, 2021, there were 0 shares of Series A Convertible Preferred Stock issued and outstanding, and 9,076 and 0 shares of Series B convertible Preferred Stock, respectively, issued and outstanding.

Common Stock

The Company has been authorized to issue 133,333,333 shares of common stock, $0.086 par value. Each share of issued and outstanding common stock shall entitle the holder thereof to fully participate in all shareholder meetings, to cast one vote on each matter with respect to which shareholders have the right to vote, and to share ratably in all dividends and other distributions declared and paid with respect to common stock, as well as in the net assets of the corporation upon liquidation or dissolution.

In February 2021, the Company issued 138,000 shares of common stock through a stock offering for the purpose of raising capital. The Company received gross proceeds of $12,420,000 for the issuance of these common shares.

In February 2021, Reliance Global Holdings, LLC, a related party, converted $3,800,000 of outstanding debt into 42,222 shares of common stock. The conversion considered the fair market value of the stock on the day of conversion of $90.00 for total shares issued as a result of 42,222.

In May 2021, the Company issued 995 shares of common stock pursuant to the acquisition of the Kush Acquisition.

In January 2022, the Company issued 178,059 shares of common stock through the Private Placement for the purpose of raising capital. See Note 9 - Warrant Liabilities for proceeds received by the Company.

In January 2022, the Company issued 40,402 shares of common stock pursuant to the Medigap Acquisition.

In January 2022, upon agreement with Series A warrant holders, 25,000 warrants were exercised at a price of $99.00 into 25,000 of the Company’s common stock.

In March 2022, the Company issued 400 shares of the Company’s common stock due to the vesting of 400 stock awards pursuant to an employee agreement.

As of March 31, 2022 and December 31, 2021, there were 755,806 and 730,407 shares of Common Stock outstanding, respectively.

Stock Options

During the year ended December 31, 2019, the Company adopted the Reliance Global Group, Inc. 2019 Equity Incentive Plan (the “Plan”) under which options exercisable for shares of common stock have been or may be granted to employees, directors, consultants, and service providers. A total of 46,667 shares of common stock are reserved for issuance under the Plan. At March 31, 2022, there were 31,027 shares of common stock reserved for future awards under the Plan. The Company issues new shares of common stock from the shares reserved under the Plan upon exercise of options.

22

The Plan is administered by the Board of Directors (the “Board”). The Board is authorized to select from among eligible employees, directors, and service providers those individuals to whom options are to be granted and to determine the number of shares to be subject to, and the terms and conditions of the options. The Board is also authorized to prescribe, amend, and rescind terms relating to options granted under the Plan. Generally, the interpretation and construction of any provision of the Plan or any options granted hereunder is within the discretion of the Board.

The Plan provides that options may or may not be Incentive Stock Options (ISOs) within the meaning of Section 422 of the Internal Revenue Code. Only employees of the Company are eligible to receive ISOs, while employees, non-employee directors, consultants, and service providers are eligible to receive options which are not ISOs, i.e. “Non-Statutory Stock Options.” The options granted by the Board in connection with its adoption of the Plan were Non-Statutory Stock Options.

The fair value of each option granted is estimated on the grant date using the Black-Scholes option pricing model or the value of the services provided, whichever is more readily determinable. The Black-Scholes option pricing model takes into account, as of the grant date, the exercise price and expected life of the option, the current price of the underlying stock and its expected volatility, expected dividends on the stock and the risk-free interest rate for the term of the option.

The following is a summary of the stock options granted, forfeited or expired, and exercised under the Plan for the three months ended March 31, 2022 and March 31, 2021 respectively:

SCHEDULE OF THE STOCK OPTIONS GRANTED, FORFEITED OR EXPIRED

|  | Options |  |  | Weighted Average Exercise Price Per Share |  |  | Weighted Average Remaining Contractual Life (Years) |  |  | Aggregate Intrinsic Value |
Outstanding at December 31, 2021 |  |  | 10,928 |  |  | $ | 232.50 |  |  |  | 2.61 |  |  | $ | - |
Granted |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Forfeited or expired |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Exercised |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Outstanding at March 31, 2022 |  |  | 10,928 |  |  | $ | 232.50 |  |  |  | 2.37 |  |  |  | - |

|  | Options |  |  | Weighted Average Exercise Price Per Share |  |  | Weighted Average Remaining Contractual Life (Years) |  |  | Aggregate Intrinsic Value |
Outstanding at December 31, 2020 |  |  | 15,594 |  |  | $ | 231.45 |  |  |  | 3.63 |  |  | $ | - |
Granted |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Forfeited or expired |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Exercised |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Outstanding at March 31, 2021 |  |  | 15,594 |  |  | $ | 228.30 |  |  |  | 3.38 |  |  | $ | - |

23

The following is a summary of the Company’s non-vested stock options as of March 31, 2022 and March 31, 2021 respectively:

SCHEDULE OF NON - VESTED STOCK OPTIONS

Options |  | Weighted Average Exercise Price Per Share |  | Weighted Average Remaining Contractual Life (Years) |
Non-vested at December 31, 2021 |  |  | 3,587 |  |  | $ | 227.10 |  |  |  | 0.90 |
Granted |  |  | - |  |  |  | - |  |  |  | - |
Vested |  |  | - |  |  |  | - |  |  |  | - |
Forfeited or expired |  |  | - |  |  |  | - |  |  |  | - |
Non-vested at March 31, 2022 |  |  | 3,587 |  |  | $ | 227.10 |  |  |  | 0.82 |

|  | Options |  |  | Weighted Average Exercise Price Per Share |  |  | Weighted Average Remaining Contractual Life (Years) |
Non-vested at December 31, 2020 |  |  | 10,636 |  |  | $ | 200.85 |  |  |  | 2.53 |
Granted |  |  | - |  |  |  | - |  |  |  | - |
Vested |  |  | - |  |  |  | - |  |  |  | - |
Forfeited or expired |  |  | - |  |  |  | - |  |  |  | - |
Non-vested at March 31, 2021 |  |  | 10,636 |  |  | $ | 223.05 |  |  |  | 2.34 |

For the three months ended March 31, 2022, the Board did not approve any options to be issued pursuant to the Plan.

As of March 31, 2022, the Company determined that the options granted had a total fair value of $2,541,360, which will be amortized in future periods through February 2024. During the three months ended March 31, 2022, the Company recognized $63,382 of compensation expense relating to the stock options granted to employees, directors, and consultants. As of March 31, 2022, unrecognized compensation expense totaled $132,364 which will be recognized on a straight-line basis over the vesting period or requisite service period through February 2024.

The intrinsic value is calculated as the difference between the market value and the exercise price of the shares on March 31, 2022. The market value as of March 31, 2022 was $64.65 based on the closing bid price for March 31, 2022.

24

As of March 31, 2021 the Company determined that the options granted had a total fair value of $3,386,156. During the three months ended March 31, 2021, the Company recognized $232,684 of compensation expense relating to the stock options granted to employees, directors, and consultants. As of March 31, 2021, unrecognized compensation expense totaled $801,698.

The intrinsic value is calculated as the difference between the market value and the exercise price of the shares on March 31, 2021. The market values as of March 31, 2021 was $65.40 based on the closing bid price for March 31, 2021.

The Company estimated the fair value of each stock option on the grant date using a Black-Scholes option-pricing model. Black-Scholes option-pricing models require the Company to make predictive assumptions regarding future stock price volatility, recipient exercise behavior, and dividend yield. The Company estimated the future stock price volatility using the historical volatility over the expected term of the option. The expected term of the options was computed by taking the mid-point between the vesting date and expiration date. The following assumptions were used in the Black-Scholes option-pricing model, not accounting for any reverse splits:

SCHEDULE OF ASSUMPTION OF BLACK-SCHOLES OPTION PRICING MODEL

|  | Three Months Ended March 31, 2022 |  |  | Three Months Ended March 31, 2021 |
Exercise price |  | $ | 0.16 - $0.26 |  |  | $ | 0.16 - $0.26 |
Expected term |  |  | 3.25 to 3.75 years |  |  |  | 3.25 to 3.75 years |
Risk-free interest rate |  |  | 0.38% - 2.43 | % |  |  | 0.38% - 2.43 | %
Estimated volatility |  |  | 293.07% - 517.13 | % |  |  | 293.07% - 517.13 | %
Expected dividend |  |  | - |  |  |  | - |
Option price at valuation date |  | $ | 0.12 - $0.27 |  |  | $ | 0.12 - $0.31 |

Warrants

As a part of the Company’s offering, the Company issued 138,000 Series A Warrants. These warrants are classified as equity warrants because of provisions, pursuant to the warrant agreement, that permit the holder obtain a fixed number of shares for a fixed monetary amount. The warrants are standalone equity securities that are transferable without the Company’s consent or knowledge. The warrants were recorded at a value per the offering of $0.15. The warrants may be exercised at any point from the effective date until the 5-year anniversary of issuance and are not subject to standard anti-dilution provisions. The Series A Warrants are exercisable at a per share exercise price equal to 110% of the public offering price of one share of common stock and accompanying Series A Warrant, $99.00. Per Common Stock above, 25,000 of these warrants were exercised in January 2022, resulting in 113,000 Series A warrants issued and outstanding at March 31, 2022.

In January 2022, as a result of the issuance of common stock in the January 2022 stock offering and the Medigap Acquisition, the Company received a deficiency notification from Nasdaq indicating violation of Listing Rule 5365(a). As part of its remediation plan, in March 2022, the Company entered into Exchange Agreements with the holders of common stock issued in January 2022. Pursuant to the Exchange Agreements, the Company issued 218,462 Series C prepaid warrants in exchange for 218,462 shares of the Company’s common stock. Additionally, as compensation for entering into the Exchange Agreements, the Company issued 81,500 Series D prepaid warrants to the January 2022 stock offering investors for no additional consideration. The fair value of the Series D prepaid warrants was treated as a deemed dividend and accordingly was treated as a reduction from income available to common stockholders in the calculation of earnings per share. Refer to Note 12, Earnings (Loss) Per Share for additional information.

Equity-based Compensation

In 2021, three employees received a signing bonus of shares of the Company’s common stock to be issued after the completion of a service period ranging from one to three years of service. The shares granted in 2021 were valued at $110,240. For the three months ended March 31, 2022, compensation expense on these grants totaled $10,328.

In 2022, two existing employees were awarded a bonus consisting of shares of the Company’s common stock to be vested immediately. The shares granted in 2022 were valued at $666,250. For the three months ended March 31, 2022, compensation expense on these grants totaled $666,250. As of March 31, 2022 these shares have not been issued.

Total stock compensation expense for the three months ended March 31, 2022 and 2021 was $739,960 and $246,966, respectively

25

NOTE 12. EARNINGS (LOSS) PER SHARE

Basic EPS applicable to common stockholders is computed by dividing earnings applicable to common stockholders by the weighted-average number of common shares outstanding.

If there is a loss from operations, diluted EPS is computed in the same manner as basic EPS is computed. Similarly, if the Company has net income but its preferred dividend adjustment made in computing income available to common stockholders results in a net loss available to common stockholders, diluted EPS would be computed in the same manner as basic EPS.

The following calculates basic and diluted EPS:

SCHEDULE OF CALCULATIONS OF BASIC AND DILUTED EPS

|  | Three Months Ended |
|  | March 31, 2022 |  |  | March 31, 2021 |
Net income (loss) |  | $ | 9,340,000 |  |  | $ | (613,926 | )
Deemed dividend |  |  | (6,930,335 | ) |  |  | - |
Net income (loss), numerator, basic computation |  |  | 2,409,665 |  |  |  | (613,926 | )
Recognition and change in fair value of warrant liabilities |  |  | (13,992,664 | ) |  |  | - |
Net income (loss), numerator, diluted computation |  | $ | (11,582,999 | ) |  | $ | (613,926 | )
Weighted average shares - denominator basic computation |  |  | 980,569 |  |  |  | 502,825 |
Effect of Series B warrant liabilities |  |  | 214,911 |  |  |  | - |
Weighted average shares, as adjusted - denominator diluted computation |  |  | 1,195,480 |  |  |  | 502,825 |
Earnings (loss) per common share - basic |  | $ | 2.46 |  |  | $ | (1.22 | )
Earnings (loss) per common share - diluted |  | $ | (9.69 | ) |  | $ | (1.22 | )

Additionally, the following are considered anti-dilutive securities excluded from weighted-average shares used to calculate diluted net loss per common share:

SCHEDULE OF ANTI-DILUTIVE SECURITIES IN WEIGHTED AVERAGE SHARES

|  | For the Three Months Ended |
|  | March 31, 2022 |  |  | March 31, 2021 |
Shares subject to outstanding common stock options |  |  | 10,928 |  |  |  | 10,928 |
Shares subject to outstanding Series A warrants |  |  | 113,000 |  |  |  | 138,000 |
Shares subject to unvested stock awards |  |  | 661 |  |  |  | 1,200 |
Shares subject to conversion of Series B preferred stock |  |  | 147,939 |  |  |  | - |
Weighted-average anti-dilutive securities |  |  | 147,939 |  |  |  | - |

26

NOTE 13. LEASES

Operating Leases

ASU 2016-02 requires recognition in the statement of operations of a single lease cost, calculated so that the cost of the lease is allocated over the lease term, generally on a straight-line basis. The standard requires a lessee to record a right-of-use asset and a corresponding lease liability at the inception of the lease, initially measured at the present value of the lease payments. The Company’s leases consist of operating leases on buildings and office space.

In accordance with ASU 2016-02, right-of-use assets are amortized over the life of the underlying leases. Lease expense for the three months ended March 31, 2022 and 2021 was $145,662 and $68,268 respectively. As of March 31, 2022, the weighted average remaining lease term and weighted average discount rate for the operating leases were 4.41 years and 5.77% respectively.

Future minimum lease payment under these operating leases consisted of the following:

SCHEDULE OF FUTURE MINIMUM LEASE PAYMENT

Year ending December 31, |  | Operating Lease Obligations |
2022 |  | $ | 371,025 |
2023 |  |  | 439,110 |
2024 |  |  | 172,690 |
2025 |  |  | 112,923 |
2026 |  |  | 113,736 |
Thereafter |  |  | 268,197 |
Total undiscounted operating lease payments |  |  | 1,477,681 |
Less: Imputed interest |  |  | 172,402 |
Present value of operating lease liabilities |  | $ | 1,305,279 |

NOTE 14. COMMITMENTS AND CONTINGENCIES

Legal Contingencies

The Company is subject to various legal proceedings and claims, either asserted or unasserted, arising in the ordinary course of business. While the outcome of these claims cannot be predicted with certainty, management does not believe the outcome of any of these matters will have a material adverse effect on our business, financial position, results of operations, or cash flows, and accordingly, no legal contingencies are accrued as of March 31, 2022 and December 31, 2021. Litigation relating to the insurance brokerage industry is not uncommon. As such the Company, from time to time have been, subject to such litigation. No assurances can be given with respect to the extent or outcome of any such litigation in the future.

Earn-out liabilities

The Company has recognized a number of earn-out liabilities resulting from contingent consideration provisions included in business combination agreements. Earn-out consideration is normally earned by acquirees when they meet or exceed pre-agreed upon earnings targets.

27

As discussed in Note 2 - Prior Period Adjustments, a $300,000 adjustment was identified for earn-out liabilities which impacted the closing December 31, 2020 balance in the same amount. Accordingly, the December 31, 2020 balance is adjusted in the following table from the originally reported balance of $2,631,418 to $2,931,418.

The following outlines changes to the Company’s earn-out liability balances inclusive of accumulated accretion for the respective period ended March 31, 2022 and December 31, 2021:

SCHEDULE OF EARN-OUT LIABILITY

|  | CCS |  |  | Fortman |  |  | Montana |  |  | Altruis |  |  | Kush |  |  | Total |
Ending balance December 31, 2021 |  | $ | - |  |  | $ | 515,308 |  |  | $ | 615,969 |  |  | $ | 992,868 |  |  | $ | 1,689,733 |  |  | $ | 3,813,878 |
Changes due to fair value adjustments |  |  | - |  |  |  | 29,522 |  |  |  | 37,741 |  |  |  | - |  |  |  | 339,808 |  |  |  | 407,071 |
Changes due to business combinations |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Changes due to payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Changes due to write-offs |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Ending balance March 31, 2022 |  | $ | - |  |  | $ | 544,830 |  |  | $ | 653,710 |  |  | $ | 992,868 |  |  | $ | 2,029,541 |  |  | $ | 4,220,949 |

|  | CCS |  |  | Fortman |  |  | Montana |  |  | Altruis |  |  | Kush |  |  | Total |
Ending balance December 31, 2020 |  | $ | 81,368 |  |  | $ | 432,655 |  |  | $ | 522,553 |  |  | $ | 1,894,842 |  |  | $ | - |  |  | $ | 2,931,418 |
Changes due to business combinations |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 1,694,166 |  |  |  | 1,694,166 |
Changes due to payments |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (452,236 | ) |  |  | - |  |  |  | (452,236 | )
Changes due to fair value adjustments |  |  | - |  |  |  | 82,653 |  |  |  | 93,416 |  |  |  | (449,738 | ) |  |  | (4,433 | ) |  |  | (278,102 | )
Changes due to write-offs |  |  | (81,368 | ) |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (81,368 | )
Ending balance December 31, 2021 |  | $ | - |  |  | $ | 515,308 |  |  | $ | 615,969 |  |  | $ | 992,868 |  |  | $ | 1,689,733 |  |  | $ | 3,813,878 |

COVID-19 pandemic contingencies

The spread of the coronavirus (COVID-19) outbreak in the United States has resulted in economic uncertainties which may negatively impact the Company’s business operations. While the disruption is expected to be temporary, there is uncertainty surrounding the duration and extent of the impact. The impact of the coronavirus outbreak on the financial statements cannot be reasonably estimated at this time.

Adverse events such as health-related concerns about working in our offices, the inability to travel and other matters affecting the general work environment could harm our business and our business strategy. While we do not anticipate any material impact to our business operations as a result of the coronavirus, in the event of a major disruption caused by the outbreak of pandemic diseases such as coronavirus, we may lose the services of our employees or experience system interruptions, which could lead to diminishment of our business operations. Any of the foregoing could harm our business and delay the implementation of our business strategy and we cannot anticipate all the ways in which the current global health crisis and financial market conditions could adversely impact our business.

Management is actively monitoring the global situation on its financial condition, liquidity, operations, industry and workforce.

NOTE 15. INCOME TAXES

The Company did not have any material uncertain tax positions. The Company’s policy is to recognize interest and penalties accrued related to unrecognized benefits as a component income tax expense (benefit). The Company did not recognize any interest or penalties, nor did it have any interest or penalties accrued as of March 31, 2022 and December 31, 2021.

The Company’s income tax provision for interim periods is generally determined using an estimate of the Company’s annual effective tax rate, adjusted for discrete items arising in the quarter. For the three months ended March 31, 2022, however, the Company calculates its income tax expense by applying to any pre-tax loss/income an effective tax rate determined as if the year-to-date period is the annual period. Using this method, for the three months ended March 31, 2022, its estimated annual effective tax rate from continuing operation was 0% and the resulting income tax expense was $0. We believe that, at this time, this method for determining the effective tax rate is more reliable than projecting an annual effective tax rate due to the uncertainty of estimating annual pre-tax loss/income under the impact of the COVID-19 pandemic. The Company’s estimated annual effective tax rate differs from the U.S. statutory tax rate primarily due to a valuation allowance recorded against the deferred tax assets. Deferred tax assets and deferred tax liabilities are recognized based on temporary differences between the financial reporting and tax basis of assets and liabilities using applicable tax rates. A valuation allowance is recorded against deferred tax assets if it is not more likely than not that some or all of the deferred tax assets will not be realized. Due to the uncertainty surrounding the realization of the deferred tax assets in future, the Company has recorded a full valuation allowance against its net deferred tax assets.

The calculation of the Company’s tax liabilities also involves assessment of uncertainties in the application of complex tax laws and regulations in the applicable jurisdictions, and a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, on the basis of technical merits. The Company’s policy is to record interest and penalties accrued related to unrecognized benefits as a component of income tax expense (benefit). The Company did not have any material uncertain tax positions, and there were no amounts for penalties or interest recorded as of March 31, 2022. Management is currently unaware of any issues under review that could result in significant payments, accruals or material deviations from its positions.

NOTE 16. RELATED PARTY TRANSACTIONS

The Company entered into a Loan Agreement with Reliance Global Holdings, LLC, a related party under common control. There is no term to the loan, and it bears no interest. Repayment will be made as the Company has business cash flows. The proceeds from the various loans were utilized to fund the acquisitions of USBA, EBS, CCS, SWMT, Fortman , Altruis, and UIS.

As of March 31, 2022, and December 31, 2021 the related party loan payable was $343,000 and $354,000 respectively.

At March 31, 2022 and December 31, 2021, Reliance Holdings owned approximately 36% and 33%, respectively, of the common stock of the Company.

NOTE 17. SUBSEQUENT EVENTS

On April 26, 2022, the Company entered into an agreement (the “APA”) with Barra &Associates, LLC (“Seller”) pursuant to which the Company purchased all of the assets of Barra & Associates, LLC for a purchase price in the amount of $7,500,000 to be paid to Barra in cash, with $6,000,000 paid at closing, $1,125,000 payable in six months from closing, and a final earnout of $375,000 payable over two years from closing based upon meeting stated milestones. The APA contains standard, commercial representations and warranties and covenants. Closing of the acquisition (“Barra Acquisition”) occurred simultaneously with the execution of the APA. The source of the cash payment is $980,000 in cash from the Company’s funds and $6,520,000 in funds borrowed from Oak Street Lending (“Loan”), the Company’s existing lender pursuant to a Fifth Amendment to Credit Agreement and Promissory Note, of even date. The purchase price is subject to post-closing adjustment to reconcile certain pre-closing credits and liabilities of the parties.

On April 26, 2022, the Company closed on a debt agreement with Oak Street to borrow a principal amount of $6,520,000 from Oak Street under a term loan to fund the Barra Acquisition pursuant to a Fifth Amendment to Credit Agreement and Promissory Note, of even date. The borrowing rate under the facility is variable and equal to Prime + 2.50%, except that during the initial period of the loan, the rate is Prime + 2.75%. The loan matures 10 years from the closing date and the service fee is .50% per year.

28

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), refers to controls and procedures that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that such information is accumulated and communicated to a company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

The Company determined it had a material weakness in its disclosure controls and procedures as it pertains to earnings per share (EPS) for the three months ended March 31, 2022. During the quarter ended March 31, 2023, the Company mitigated this deficiency by consulting with qualified advisors that have in-depth EPS expertise. These advisors will assist the Company in the calculations and disclosures of EPS for future reporting periods. Pursuant to the above, our Chief Executive Officer and Chief Financial Officer have evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2022, concluding them to be ineffective as of such date.

Changes in Internal Control over Financial Reporting

There have not been any changes in our internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act, during our most recently completed fiscal quarter which is the subject of this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

29

PART II

Item 6. Exhibits

The following exhibits are filed or furnished herewith, as the case may be.

Exhibit No. |  | Description
3.1 |  | Amendment to the Company’s Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the registrant’s Current Report on Form 8-K filed with the SEC on January 6, 2022).
4.1 |  | Form of Series C Warrant (incorporated by reference to Exhibit 4.1 to the registrant’s Current Report on Form 8-K filed with the SEC on March 24, 2022).
4.2 |  | Form of Series D Warrant (incorporated by reference to Exhibit 4.2 to the registrant’s Current Report on Form 8-K filed with the SEC on March 24, 2022).
10.1 |  | Asset Purchase Agreement entered into on January 10, 2022, and dated as of December 21, 2021, by and among the registrant, Medigap Healthcare Insurance Company, LLC and Joseph J. Bilotti III (incorporated by reference to Exhibit 10.1 to the registrant’s Current Report on Form 8-K filed with the SEC on January 14, 2022).
10.2 |  | Form of Investor Exchange Agreement (incorporated by reference to Exhibit 10.1 to the registrant’s Current Report on Form 8-K filed with the SEC on March 24, 2022).
10.3 |  | Form of Medigap Exchange Agreement (incorporated by reference to Exhibit 10.2 to the registrant’s Current Report on Form 8-K filed with the SEC on March 24, 2022).
31.1 |  | Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act 2002*
31.2 |  | Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act 2002*
32.1 |  | Section 1350 Certification of the Chief Executive Officer and Chief Financial Officer**
101.INS* |  | Inline XBRL Instance Document
101.CAL* |  | Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.SCH* |  | Inline XBRL Taxonomy Extension Schema Document
101.DEF* |  | Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB* |  | Inline XBRL Taxonomy Extension Labels Linkbase Document
101.PRE* |  | Inline XBRL Taxonomy Extension Presentation Linkbase Document
104 |  | Cover Page Interactive Data File (formatted in IXBRL, and included in exhibit 101).

* | Filed herewith
** | Furnished herewith

30

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

| Reliance Global Group, Inc.
Date: May 18, 2023 | By: | /s/ Ezra Beyman
|  | Ezra Beyman
|  | Chief Executive Officer
|  | (principal executive officer)
Date: May 18, 2023 | By: | /s/ Joel Markovits
|  | Joel Markovits
|  | Chief Financial Officer
|  | (principal financial officer and principal accounting officer)

31